[go: up one dir, main page]

WO2016177900A1 - Agents antibactériens et utilisation thérapeutique de ceux-ci - Google Patents

Agents antibactériens et utilisation thérapeutique de ceux-ci Download PDF

Info

Publication number
WO2016177900A1
WO2016177900A1 PCT/EP2016/060233 EP2016060233W WO2016177900A1 WO 2016177900 A1 WO2016177900 A1 WO 2016177900A1 EP 2016060233 W EP2016060233 W EP 2016060233W WO 2016177900 A1 WO2016177900 A1 WO 2016177900A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
composition
bacterial
peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/060233
Other languages
English (en)
Inventor
Marit Otterlei
Aina NEDAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norwegian University of Science and Technology NTNU
Original Assignee
Norwegian University of Science and Technology NTNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwegian University of Science and Technology NTNU filed Critical Norwegian University of Science and Technology NTNU
Publication of WO2016177900A1 publication Critical patent/WO2016177900A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0047—Ultraviolet radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel agents, particularly peptides or mimetics thereof and their encoding nucleic acids, pharmaceutical compositions comprising at least one of said agents, and their use as anti-bacterials, e.g. in the treatment or prevention of bacterial infections.
  • the agents may be useful alone or in combination with other anti-bacterial compounds, such as e.g. antibiotics etc.
  • therapeutic methods which comprise the use of said agents and compositions for the aforementioned uses.
  • the agents may also be used in the manufacture or preparation of medicaments for the aforementioned therapies.
  • the agents may be used in in vitro methods, e.g. in cell culture methods (to prevent or inhibit bacterial growth or to prevent or reduce unwanted bacterial colonisation or contamination in a non-medical (e.g. in vitro or ex vivo) setting, for example for sterilisation or antiseptic purposes) and in the production of products coated with the agent (e.g. medical devices, implants etc).
  • products coated with the agent are also provided.
  • Infectious diseases also known as transmissible diseases or communicable diseases, comprise clinically evident illness, i.e. symptoms of disease, resulting from the infection, presence and growth of pathogenic biological agents, e.g.
  • infectious diseases may be asymptomatic for much or even all of their course in a given host. In the latter case, the disease may only be defined as a "disease” (which by definition means an illness) in hosts who secondarily become ill after contact with an asymptomatic carrier.
  • Bacterial infections do not always result in, or progress to, a clinically overt or symptomatic disease or disease state. For instance, a wound may become infected by one or more bacteria, without resulting in an infectious disease.
  • bacterial growth in and on a subject may occur naturally, e.g.
  • a bacterial, infection may be viewed as any atypical, unwanted, undesirable, excessive and/or harmful infection and does not necessarily involve or result in a disease.
  • bacterial pathogen Transmission of a bacterial pathogen can occur in various ways including physical contact, contaminated food, body fluids, objects, airborne inhalation, or through vector organisms. Infectious diseases are sometimes called "contagious" when they are easily transmitted by contact with an ill person or their secretions. Thus, a contagious disease is a subset of infectious disease that is especially infective or easily transmitted.
  • infectious diseases are one of the main contributors to global mortality and morbidity and a huge amount of effort has gone into the discovery and development of anti-bacterial compounds, for both the treatment and prevention of infectious diseases.
  • bacterium could display intrinsic resistance to these drugs or could develop resistance to these drugs.
  • Resistance of a bacterium to an antibiotic can be viewed as a substantially greater tolerance, or reduced susceptibility, to the antibiotic compared to a sensitive bacterium or a typical or a wild type version of the bacterium.
  • a bacterium can be completely unaffected by exposure to an antibiotic. In this instance the bacterium can be considered fully resistant to that antibiotic.
  • Multidrug resistance (MDR) in bacteria describes the situation where a bacterium is resistant to at least three classes of drugs, specifically in the context of bacteria, at least three classes of anti-bacterial agents. Antibiotics in one class are functionally unrelated, structurally unrelated, or both, to antibiotics in a different class. MDR in bacteria is thus often termed multiple anti-bacterial drug resistance or multiple antibiotic resistance. The terms are used interchangeably in the art and herein. Bacteria displaying multidrug resistance phenotypes (or multiple antibacterial/antibiotic drug resistance phenotypes) are referred to as MDR bacteria (or sometimes MAR bacteria). Again, these terms are used interchangeably in the art and herein.
  • Anti-bacterial resistance mechanisms are numerous. For instance, resistance may arise from cell impermeability, which physically prevents the antibacterial from reaching its site of action in or on the cell; efflux mechanisms which prevent effective amounts of the anti-bacterial reaching its site of action in or on the bacterium by rapidly removing the anti-bacterial from the cell; metabolic
  • development (or acquisition) of resistance can be through mutation. For instance, this may involve changes in the structure of the target of the anti-bacterial that reduces the sensitivity of the target to the anti-bacterial. It can also be a mutation in a pathway involved in the regulation of the cellular machinery involved in the metabolism or efflux of the anti-bacterial.
  • TLS in bacteria contributes to the acquisition of antibiotic resistance, e.g. in MDR strains.
  • TLS is a cellular mechanism to tolerate DNA damage in which specific DNA polymerases (TLS polymerases) are expressed that are capable of by-passing and leaving the DNA lesions in DNA for the possibility of removal later, thereby enabling the cell to complete the duplication of its genome.
  • TLS polymerases specific DNA polymerases
  • this damage tolerance mechanism is error-prone because TLS polymerases are commonly low-fidelity enzymes and insert bases in a non-Watson Crick manner opposite the lesion and opposite undamaged DNA, and thus their inaccurate synthesis introduces mutations. It is thought that these mutations contribute to genetic diversity in bacteria and facilitate the acquisition of antibiotic resistance, particularly in MDR strains.
  • MDR species and strains of bacterium exist today.
  • bacterial genera from which MDR species and strains pose significant problems for human and animal health include, but are not limited to Pseudomonas,
  • Acinetobacter Burkholderia, Klebsiella, Providencia, Enterococcus and
  • APIM peptides are a group of peptides that interact with PCNA (proliferating cell nuclear antigen) via a novel PCNA interacting motif (Gilljam et al., 2009.
  • APIM AlkB homologue 2 (hABH2) PCNA-interacting motif
  • the PCNA binding motif found in APIM peptides typically is defined using the consensus sequence [R/K]-[F/W Y]-[L/IA /A]- [L/IA /A]-[K/R] (SEQ ID NO: 1 ).
  • PCNA is a member of the sliding clamp family of proteins, which is known to be involved in both DNA replication and DNA repair.
  • the main function of PCNA is to provide replicative polymerases with the high processivity needed for duplication of the genome.
  • PCNA tagged with green fluorescent protein (GFP) forms distinct foci representing sites of replication. It can therefore be used as an S-phase marker.
  • APIM peptides have been shown to be useful in therapy. Specifically APIM peptides have been shown to be effective in sensitizing animal cells to cytotoxic and cytostatic agents, particularly DNA-damaging agents (WO 2009/104001 ) and indeed as an apoptosis-inducing cytotoxic agent in its own right (MQIIer et al., 2013. Targeting Proliferating Cell Nuclear Antigen and Its Protein Interactions Induces Apoptosis in Multiple Myeloma Cells, PLOS One, 8(7), e70430, pp.1 -12).
  • APIM peptides have been shown to be useful in combination with cytotoxic and/or cytostatic agents in the treatment of a disorder or condition where it is desirable to inhibit the growth of endogenous cells, or in a treatment which involves cytostatic therapy, i.e. to prevent or inhibit the unwanted proliferation of endogenous cells.
  • APIM peptides also have a direct effect on bacteria, i.e. APIM peptides have direct cytotoxic effects on a variety of bacterial cells and also potentiate or enhance the effect of other anti-bacterial agents on bacterial cells, i.e. sensitize bacterial cells to various anti-bacterial agents, e.g. antibiotics, particularly agents that act intracellularly rather than agents that function at the cell membrane or cell wall, e.g. to permeabilize cells (see e.g. International application No. PCT/EP2014/073967).
  • APIM peptides may interact with sliding clamp DNA proteins in bacteria, thereby affecting DNA replication and repair in bacterial cells, resulting in cytotoxicity and/or reduction in cell growth.
  • APIM peptides may be able to interfere with the interaction of e.g. TLS polymerases, and other DNA repair proteins, and sliding-clamp proteins (e.g. the ⁇ - clamp), thereby inhibiting essential cellular functions, particularly DNA synthesis and repair, resulting in the stimulation of apoptosis or apoptosis-like cell death, or increased sensitivity of the bacterial cells to other anti-bacterial agents.
  • APIM peptides are capable of inducing apoptosis in animal cells, e.g. human cells, alone, i.e. APIM peptides can be cytotoxic to animal cells.
  • This property makes APIM peptides less attractive for use as anti- bacterial agents, e.g. in the treatment or prevention of bacterial infections, because said peptides may have a detrimental effect on endogenous cells in the animal (e.g. human) being treated.
  • APIM peptides used in the treatment or prevention of bacterial infections in an animal may have undesirable side effects.
  • bacterial infections particularly diseases, disorders or conditions caused by, or associated with, bacterial infections (e.g. infectious diseases caused by, associated with, or exacerbated by, bacteria), which also have minimal side effects, e.g. anti-bacterials that are not cytotoxic to animal cells.
  • the inventor has surprisingly determined that peptides containing a derivative of an APIM sequence, RLVPK (SEQ ID NO: 2), are effective as anti-bacterial agents, but do not have cytotoxic effects on animal cells.
  • the anti-bacterial activity of such peptides is particularly unexpected as the derivative sequence does not fall within the APIM consensus motif described above and does not bind to PCNA with substantial affinity.
  • the peptides of the invention find particular utility in the treatment or prevention of bacterial infections in animal (e.g. human) subjects.
  • oligopeptidic compounds e.g. peptides
  • RLVPK peptide sequence RLVPK
  • the inventors have unexpectedly determined that oligopeptidic compounds comprising SEQ ID NO: 2 (the "motif") and an uptake peptide can be imported into bacterial cells (exemplified with both gram negative and gram positive bacteria), wherein the compounds have an anti-bacterial effect, e.g.
  • oligopeptidic compounds described herein may find utility as anti-bacterial agents alone and/or may enhance the effect of other anti-bacterial agents.
  • agents may also potentiate the effects of DNA damaging radiation, particularly UV radiation.
  • the introduction of the agents described herein may be useful in the treatment of septicaemia (an infection of the blood) or oral administration may be useful in the treatment of, e.g. gastric ulcers caused by a bacterial infection, such as Helicobacter pylori (a gram negative bacterium), or other infected wounds etc.
  • a bacterial infection such as Helicobacter pylori (a gram negative bacterium), or other infected wounds etc.
  • the agents defined herein may be effective in the treatment of a number of bacterial infections including various infectious diseases, e.g. bacterial infections, or conditions caused or exacerbated by, or associated with, an infectious disease.
  • peptides of the invention act by interfering with DNA replication and repair mechanisms. This is different to mechanism of action for many known anti-bacterials, which commonly act by inhibiting cell wall synthesis, e.g. beta-lactams (such as penicillins, cephalosporins, carbapenems,
  • the anti-bacterial agents of the present invention may be particularly useful in combating diseases or conditions caused by MDR bacteria, because the agents act on a different part of the cellular machinery to which resistance mechanisms have not yet evolved. Moreover, the anti-bacterial agents of the present invention may interfere with the mechanisms associated with the acquisition of MDR.
  • a biofilm is a collection, or community, of bacteria, surrounded by a matrix of extracellular polymers (also known in the art as a glycocalyx). These extracellular polymers are typically polysaccharides, notably polysaccharides produced by the organisms themselves, but they can contain other biopolymers as well.
  • a biofilm will typically be attached to a surface, which may be inert or living, but it has also been observed that biofilms may form from bacteria attached to each other or at any interface.
  • a biofilm is characterised as a highly organised multicellular community of bacteria encased in, or surrounded by, an extracellular polymer matrix, generally a polysaccharide matrix, and typically in close association with a surface or interface.
  • an extracellular polymer matrix generally a polysaccharide matrix, and typically in close association with a surface or interface.
  • Such a mode of growth is protective to the bacteria and renders them difficult to remove or eradicate (for example, as discussed further below, recalcitrant or resistant to anti-bacterial agents or host defence or clearance mechanisms).
  • Biofilms cause significant commercial, industrial and medical problems, in terms of infections, contamination, fouling and spoilage etc, and thus the present invention provides a significant advantage in enabling or facilitating the combating of such biofilms, including both reducing or preventing their formation, and rendering them more susceptible to removal or reduction, e.g. more susceptible to the effect of anti-bacterial agents (including disinfectants or antibiotics) or indeed in the case of an infection, to the immune response of the infected host.
  • anti-bacterial agents including disinfectants or antibiotics
  • the efficacy of anti-bacterial agents both therapeutic and non-therapeutic and including particularly antibiotics, may thus be enhanced.
  • Biofilms are found ubiquitously on a wide variety of surfaces or interfaces (e.g. water/solid and water/gas (for example water/air) interfaces) if conditions conducive to bacterial colonisation exist. Basically a biofilm will form wherever there are bacteria and an interface or surface, particularly a surface exposed to water or moisture and biofilms are now recognised as the natural state of bacterial growth on such surfaces or interfaces.
  • surfaces or interfaces e.g. water/solid and water/gas (for example water/air) interfaces
  • bacteria in a biofilm community display properties at the cellular level (phenotype) that are not shared by their planktonic (free-floating) equivalents. In fact, it is believed that bacteria in a biofilm are profoundly different from planktonic free-floating cells. Further differences can also be observed at the community level and are attributed to the effects of the extracellular matrix. Perhaps most notable is the commonly observed phenomenon that bacteria in a biofilm environment do not display the same susceptibilities to anti-bacterial agents, e.g. antibiotics and microbicides, and host immune defences or clearance mechanisms.
  • biofilms may form in the case of bacterial infections i.e. within or on an infected host.
  • biofilm formation may also occur on a "physiological" or “biological” surface, that is on an animate or biotic surface, or a surface on or in an infected host organism (e.g. a human or non-human animal subject), for example on an internal or external body or tissue surface.
  • Such biofilm formation (or infection) on body tissues is increasingly believed to contribute to various infective diseases, including for example native valve endocarditis (mitral, aortic, tricupsid, pulmonic heart valves), acute otitis media (middle ear), chronic bacterial prostatitis (prostate), cystic fibrosis (lungs), pneumonia (respiratory tract), periodontitis (tissues supporting the teeth, e.g. gingiva, periodontal ligament, alvelor bone).
  • native valve endocarditis mitral, aortic, tricupsid, pulmonic heart valves
  • acute otitis media middle ear
  • chronic bacterial prostatitis prostate
  • cystic fibrosis lungs
  • pneumonia respiratory tract
  • periodontitis tissues supporting the teeth, e.g. gingiva, periodontal ligament, alvelor bone.
  • Biofilm niches are also present when medical devices are implanted and the formation of biofilm on such implanted ("in-dwelling") devices can lead to clinical problems with bacterial infection at such sites, such as prosthetic valve endocarditis and device-related infection, for example with intrauterine devices, contact lenses, prostheses (e.g. prosthetic joints) and at catheterisation sites, for example with central venous or urinary catheters.
  • biofilm infections A significant problem and risk with such biofilm infections is that bacteria (or more particularly microcolonies) may break off or detach from the biofilm, and enter other tissues, including significantly the circulation. Such circulating biofilm-derived bacteria can cause further infections and lead to significant clinical problems, particularly as the detached circulating bacteria may have all the resistance characteristics of the parent community.
  • Body or tissue surfaces which are dead or damaged are particularly susceptible to biofilm infection.
  • Wounds are susceptible to infection and biofilm formation can occur in wounds that do not heal in a short amount of time. Wounds are an ideal environment for the formation of biofilms due to their susceptibility to bacterial colonisation and the availability of substrate and surface for biofilm attachment. Problematically, infection of a wound often delays healing further and thus renders that wound more susceptible to biofilm formation and established infection. Wounds in which healing is delayed (so called chronic wounds) represent sites of particular concern with respect to biofilm formation.
  • evidence is increasingly growing that both chronic and acute wounds may be sites of biofilm infection, with evidence of diverse bacterial communities or populations in wounds, particularly chronic wounds, including anaerobic bacteria within chronic wounds.
  • Biofilm based infection is very difficult to treat and biofilm contamination is very difficult to eradicate.
  • biofilm contamination is very difficult to eradicate.
  • any means of improving or enabling the combating of biofilms would be very important, both clinically and commercially.
  • the peptides of the invention will be effective as anti-biofilm agents, e.g. capable of inhibiting or preventing the formation of (bacterial) biofilms. Accordingly, the present invention may be seen also to provide new methods and means (i.e. agents) for combating (bacterial) biofilm, in vitro (e.g. on a product, material, device or implant), in vivo (e.g. at a wound site, including a surgical wound, a implant site etc.) or ex vivo.
  • agents for combating (bacterial) biofilm, in vitro (e.g. on a product, material, device or implant), in vivo (e.g. at a wound site, including a surgical wound, a implant site etc.) or ex vivo.
  • the invention can be seen to provide a method of treating or preventing a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection, said method comprising administering (particularly administering an effective amount of) an agent comprising or encoding a peptide comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) or a composition (e.g. a
  • composition containing an agent comprising or encoding a peptide comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) to a subject in need thereof.
  • the invention provides an agent comprising or encoding a peptide comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) or a composition (e.g. a pharmaceutical composition) containing an agent comprising or encoding an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK), for use in treating or preventing a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection.
  • an agent comprising or encoding an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) in the manufacture of a medicament for the treatment or prevention of a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection.
  • the invention provides a method of treating or preventing a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection, said method comprising administering (particularly administering an effective amount of) an agent or a composition (e.g. a pharmaceutical composition) containing an agent to a subject in need thereof, wherein said agent comprises:
  • an oligopeptidic compound comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates the cellular uptake of said compound;
  • an agent or a composition containing an agent for use in treating or preventing a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection, wherein said agent comprises:
  • an oligopeptidic compound comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates the cellular uptake of said compound;
  • an agent in the manufacture of a medicament for the treatment or prevention of a bacterial infection more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection
  • said agent comprises:
  • an oligopeptidic compound comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates the cellular uptake of said compound;
  • the invention provides a method of treating or preventing a bacterial infection, said method comprising administering an agent, or a composition containing an agent, to a subject in need thereof, wherein said agent comprises:
  • an oligopeptidic compound comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates the cellular uptake of said compound;
  • the invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises:
  • an oligopeptidic compound comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates the cellular uptake of said compound, or
  • the invention provides the use of an agent in the manufacture of a medicament for the treatment or prevention of a bacterial infection in a subject, wherein said agent comprises:
  • an oligopeptidic compound comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates the cellular uptake of said compound;
  • the agent may be used in combination with one or more additional active agents, e.g. an antibiotic, in order to enhance the effect of that additional active agent, or to sensitise cells to the effect of said additional active agent, e.g. antibiotic.
  • additional active agents e.g. an antibiotic
  • the agent as defined herein may be used alone, i.e. as the only active agent capable of preventing or inhibiting bacterial growth (e.g. having anti-bacterial activity) in a composition and/or medicament.
  • a method of treating or preventing a bacterial infection comprising administering an agent or composition as defined herein, and separately, simultaneously or sequentially administering of one or more additional active agents, e.g. an antibiotic, to a subject in need thereof.
  • an agent or composition as defined herein, and separately, simultaneously or sequentially administering of one or more additional active agents, e.g. an antibiotic, to a subject in need thereof.
  • an agent or composition as defined herein for use in combination with one or more additional active agents e.g. an antibiotic, in the treatment or prevention of a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection.
  • an agent as defined herein in the manufacture of a medicament for use in combination with one or more additional active agents, e.g. an antibiotic, in the treatment or prevention of a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection.
  • additional active agents e.g. an antibiotic
  • the invention provides a method of treating or preventing a bacterial infection, said method comprising administering an agent or composition as defined herein, and separately, simultaneously or sequentially administering of one or more additional active agents, e.g. an antibiotic, to a subject in need thereof.
  • additional active agents e.g. an antibiotic
  • an agent or composition as defined herein for use in combination with one or more additional active agents e.g. an antibiotic, in the treatment or prevention of a bacterial infection.
  • an agent as defined herein in the manufacture of a medicament for use in combination with one or more additional active agents, e.g. an antibiotic, in the treatment or prevention of a bacterial infection.
  • additional active agents e.g. an antibiotic
  • the medicament may further comprise one or more additional active agents, such as an antibiotic.
  • the medicament may be in the form of a single composition comprising both the agent as defined herein and the one or more additional active agents, e.g. antibiotic, or it may be in the form of a kit or product containing them for separate (e.g. simultaneous or sequential) administration.
  • additional active agents e.g. antibiotic
  • an agent as defined herein in the manufacture of a medicament for the treatment or prevention of a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection, wherein the medicament is administered separately, simultaneously or sequentially with one or more additional active agents, e.g. an antibiotic.
  • the invention provides a product containing an agent as defined herein together with one or more additional active agents, e.g. an antibiotic, as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of a bacterial infection, more particularly a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection.
  • additional active agents e.g. an antibiotic
  • the invention provides a product containing an agent as defined herein together with one or more additional active agents, e.g. an antibiotic, as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of a bacterial infection.
  • additional active agents e.g. an antibiotic
  • the agent as defined herein may be used to modulate or potentiate the effect of one or more additional active agents, e.g. an antibiotic.
  • the agent may sensitize the bacterial cell to the one or more additional active agents, e.g. an antibiotic.
  • the one or more additional active agents such as an antibiotic, may enhance, augment or improve the anti- bacterial effect of the agent defined herein.
  • the agents defined herein may have the advantage of enabling lower doses of anti-bacterial agents to be effective and/or improving the efficacy of anti-bacterials against resistant strains.
  • the agent may be used in combination with DNA damaging radiation, e.g. UV radiation, in order to enhance the effect of the radiation, or to sensitize cells to the effect of said radiation, e.g. UV radiation.
  • DNA damaging radiation e.g. UV radiation
  • UV radiotherapy also known as UV radiation therapy or UV light therapy
  • UV radiation therapy may be used in the treatment of various bacterial infections.
  • UV radiotherapy is meant the use of UV radiation, preferably UVC radiation, i.e. radiation with a wavelength of 200 nm to 290 nm.
  • UV radiotherapy is often unsuccessful at completely eradicating bacterial cells from a patient because it is often not possible to deliver a sufficiently high dose of local radiation to kill bacterial cells without an unacceptably high risk of damage to the surrounding normal tissue at the site of infection. It is also known that bacterial cells show widely varying susceptibilities to radiation- induced cell death and ionizing radiation may only inhibit further cell growth, rather than eradicating the bacterial cells as such. Thus, there is a need to enhance the efficacy of radiotherapy by sensitizing bacterial cells to the effects of ionizing UV radiation.
  • the agents and compositions of the invention may be used to provide such a sensitizing effect, in other words to enhance (or alternatively put to increase, augment, or potentiate) the effects of UV radiotherapy, particularly UVC radiotherapy, or to render bacterial cells, which may be present in an infection site in a subject, more susceptible to the effects of said radiotherapy.
  • they may find utility in any anti-bacterial application where radiotherapy is used. This may include any situation where it is desired to kill, inhibit or eradicate bacterial cells, e.g. at an infection site or in vitro.
  • the agents and compositions of the invention may thus be used as a sensitizer of bacterial cells, to the effects of UV radiation.
  • sensitizer is meant the use of the agents and compositions of the invention to enhance the effect of UV radiation on bacterial cells. This may be achieved by the inhibition of the
  • the present invention encompasses an agent, or a composition containing an agent, for use as a sensitizer for UV radiotherapy in the treatment or prevention of a bacterial infection in a subject, or in the treatment or prevention of a bacterial infection in subject which involves UV radiotherapy (e.g. UVC
  • radiotherapy wherein said agent comprises:
  • an oligopeptidic compound comprising an an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates the cellular uptake of said compound;
  • the methods of treatment defined above may comprise UV radiotherapy (e.g. UVC radiotherapy), which may be administered simultaneously, sequentially or separately to said agent or composition.
  • UV radiotherapy e.g. UVC radiotherapy
  • UV radiation may be particularly useful for the treatment of topical infections, e.g. infections of the skin or mucosal membranes, such as the oral cavity, oesophagus and/or eye.
  • the agent or composition for use as a sensitizer for UV radiation, or for use in methods comprising UV radiotherapy may be formulated for topical administration, e.g. to the skin and/or muscosal membrane.
  • the invention is not limited to this aspect, as the agents and compositions of the invention may be combined with UV radiation to treat infections by other means, e.g. endoscopically or ex vivo.
  • a blood infection may be treated by administering the agent or composition of the invention to a subject and subsequently or contemporaneously irradiating the blood of said subject by circulating the blood through an external tube exposed to UV radiation, i.e. akin to a dialysis machine.
  • a bacterial infection includes any bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection.
  • bacterial infections do not always result in, or progress to, a disease or disease state.
  • a bacterial infection may be viewed specifically as a bacterial infection that is not associated with a disease or condition.
  • the above therapeutic uses and methods may be viewed as the treatment or prevention of an atypical, unwanted, undesirable, excessive and/or harmful bacterial infection and/or a bacterial infectious disease or a disease or condition exacerbated or caused by a bacterial infection.
  • the agent or composition as defined herein may be used as an anti-bacterial agent in in vitro or ex vivo methods, e.g. in methods of cell culture or where the agent is used in the context of an abiotic or inanimate setting, e.g. to treat an inanimate surface to prevent, inhibit or reduce bacterial colonisation and/or growth, e.g. for decontamination, antiseptic or sterilisation purposes, or is applied to or contacted with a surface, material, substrate, product, device or system susceptible to bacterial growth, e.g.
  • the invention also provides an in vitro or ex vivo method of
  • an agent or composition as defined herein to a bacterial cell or cell culture, i.e. to inhibit or prevent the growth of one or more bacteria.
  • This may allow the identification and/or characterisation of agents as defined, e.g. to determine the dose at which the agent is effective or determine which bacteria are particularly susceptible.
  • the in vitro methods may be useful to identify other antibacterial compounds, e.g. compounds that are weakly anti-bacterial when used on their own, but which have useful anti-bacterial activity when used in combination with the agent of the invention.
  • the invention provides the use of an agent or composition as defined herein in in vitro or ex vivo methods, e.g. bacterial cell culture or in the context of an abiotic or inanimate setting, e.g.
  • an inanimate surface or product or material etc, e.g. as listed above
  • bacterial colonisation and/or growth e.g. for decontamination, antiseptic or sterilisation purposes, or for application or administration to a surface or system (etc, as above) susceptible to bacterial growth, e.g. contamination.
  • the invention provides an in vitro method of: (i) preventing, inhibiting or reducing bacterial colonisation and/or growth in or on a surface, product or material; or
  • an agent or composition as defined herein comprising administering an agent or composition as defined herein to a surface, product or material susceptible to bacterial growth or a bacterial cell or a cell culture, optionally simultaneously, sequentially or separately administering one or more additional active agents to said surface, product or material, cell or cell culture.
  • the method further comprises a step of exposing said surface, product or material to UV radiation, prior to, contemporaneously with, or after administering said agent or composition.
  • the agent or composition as defined herein is used to prevent a bacterial infection or contamination, e.g. in circumstances where there is an increased probability of an infection, such as in surgery or in the treatment of a wound.
  • the agent or composition as defined herein may be provided or administered via a product, device, implant or material to which the agent or composition has been applied, impregnated or chemically bonded.
  • the oligopeptidic compounds defined herein are commonly positively charged and such compounds will readily adhere to various surfaces without the need for additional adhesives.
  • adhesives or other methods of bonding the agents of the invention to products, devices, implants or materials is contemplated herein.
  • a further aspect of the invention comprises the provision of a product, material, device or implant which is coated, impregnated or chemically bonded with an agent or composition as described herein.
  • the invention also extends to the use of such products, materials, devices or implants in the methods and uses as described herein.
  • yet another aspect of the invention comprises a method of producing product, material, device or implant (e.g. an aseptic product, material, device or implant) which is coated, impregnated or chemically bonded with an agent or composition as defined herein, comprising providing a product, material, device or implant and coating or impregnating said device with said agent or composition, or chemically bonding said agent or composition to said product, material, device or implant.
  • product, material, device or implant e.g. an aseptic product, material, device or implant
  • an agent or composition as defined herein
  • the agents and compositions of the invention may also be used to combat bacterial biofilms, including both on biotic and abiotic surfaces.
  • the methods and uses discussed above may be for use in combating bacterial biofilm infection or to combat bacterial biofilm formation on inanimate surfaces e.g. for disinfection and cleaning purposes.
  • the bacterial infection or bacterial colonisation and/or growth may be a biofilm.
  • the invention may provide a method of preventing or inhibiting the formation of a bacterial biofilm on a product, material, device or implant, said method comprising:
  • the invention provides an oligopeptidic compound (an agent) (e.g. a peptide) comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates the cellular uptake of said compound.
  • an agent e.g. a peptide
  • RLVPK amino acid sequence set forth in SEQ ID NO: 2
  • the invention provides a nucleic acid molecule encoding an oligopeptidic compound (e.g. a peptide) as defined above. Also provided is the complement of such a nucleic acid molecule.
  • a further aspect relates to a vector comprising said nucleic acid molecule or complement, which is defined further below.
  • the oligopeptidic compoundor its encoding nucleic acid may function in the methods and uses of the invention, the compound must be capable of entering the bacterial cell, i.e. crossing the cell membrane and cell wall, if present, into the cytosol (cytoplasm). Whilst this may be achieved using any convenient mechanism, such as with a liposome, as noted above, the inventors have surprisingly and advantageously found that uptake of the oligopeptidic compound may be achieved by associating the anti-bacterial motif (SEQ ID NO: 2) with one or more molecules that are known to be capable of facilitating the uptake of molecules into animal cells, e.g. an import peptide.
  • SEQ ID NO: 2 anti-bacterial motif
  • an oligopeptidic compound that comprises a domain that assists the transit of the compound across the cell membrane, i.e. to generate a fusion peptide or chimeric peptide (a peptide formed from two or more domains that are not normally found together in nature).
  • a peptide comprising a cell membrane permeable motif e.g. a cell penetrating peptide (an uptake or import peptide, or a peptide transduction domain).
  • the fusion peptide may optionally comprise additional sequences, as discussed further below.
  • oligopeptidic compound comprises an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and a domain that facilitates its uptake
  • the compound comprises more than 5 residues and the final size of the compound will be dependent on the size and number of the domains that make up said compound, i.e. the amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and uptake (import) peptide may be viewed as domains of the oligopeptidic compound.
  • a domain may be viewed as a distinct portion (i.e. a sequence within the full-length peptidic sequence) of the oligopeptidic compound that can be assigned or ascribed a particular function or property.
  • the oligopeptidic compound of the invention comprises at least 2 domains, i.e. the amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) and the domain that facilitates the cellular uptake of said compound, e.g. uptake (import) peptide sequence domain.
  • the oligopeptidic compound may comprise additional domains that may facilitate its function and/or stability, e.g. the capacity of the peptide to interact with its target, e.g. the ⁇ -clamp protein from bacteria, e.g. E.coli.
  • the oligopeptidic compound may comprise at least 2, 3, 4 or 5 domains, e.g. 6, 7, 8, 9, 10, 12, 15 or more domains.
  • the oligopeptidic compound may comprise one or more linker domains, i.e. a domain that interspaces between two other domains, i.e. occupies the space in between and connects two domains of the oligopeptidic compound.
  • signal peptides such as nuclear localization signal (NLS) sequences
  • the oligopeptidic compound may comprise a domain that is capable of directing the oligopeptidic compound to a cellular or subcellular location, e.g. a signal peptide (also known as a target or transit peptide), such as a nuclear localization signal (NLS) sequence.
  • the one or more linker domains may have an additional function, e.g. a linker domain may also function as a signal peptide, e.g. a NLS.
  • a signal peptide domain may function as a linker domain in some embodiments, e.g. an NLS sequence may be used as a linker domain.
  • the oligopeptidic compound may comprise a domain comprising an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK), a domain that facilitates its cellular uptake (e.g. an uptake (import) peptide sequence domain) and a linker domain.
  • the oligopeptidic compound may also comprise a nuclear localisation signal sequence domain.
  • the nuclear localization signal sequence domain may function as a linker domain.
  • the agent of the invention may take the form of a construct containing (i.e. comprising) an oligopeptidic compound which comprises an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) together with a domain that facilitates its cellular uptake (e.g. an uptake peptide sequence) and optionally additional domains.
  • an oligopeptidic compound which comprises an amino acid sequence set forth in SEQ ID NO: 2 (RLVPK) together with a domain that facilitates its cellular uptake (e.g. an uptake peptide sequence) and optionally additional domains.
  • oligopeptidic compounds containing an amino acid sequence set forth in SEQ ID NO: 2 may function by interfering with (e.g. inhibiting) interactions between the ⁇ -clamp protein and proteins that interact with the ⁇ -clamp protein.
  • the oligopeptidic compound is preferably an isolated compound, e.g. an isolated peptide and most preferably the oligopeptidic compound is a synthetic compound, e.g. a synthetic peptide.
  • the nucleic acid molecule encoding the oligopeptidic compound is preferably an isolated nucleic acid molecule and most preferably the nucleic acid molecule is a synthetic nucleic acid molecule.
  • the oligopeptidic compound and its encoding nucleic acid molecule are non- native, i.e. non-naturally occurring, molecules.
  • the domain that facilitates the uptake of the oligopeptidic compound may be an uptake (import) peptide sequence, which may be a sequence which acts to transport the oligopeptidic compound into a cell, or across a cell membrane (i.e. into the interior of a cell). It may thus be a so-called “cell penetrating” sequence (or more particularly “cell penetrating peptide”) also known in the art as a protein transduction domain (PTD) or protein transduction sequence.
  • uptake (import) peptide sequence which may be a sequence which acts to transport the oligopeptidic compound into a cell, or across a cell membrane (i.e. into the interior of a cell). It may thus be a so-called “cell penetrating” sequence (or more particularly "cell penetrating peptide”) also known in the art as a protein transduction domain (PTD) or protein transduction sequence.
  • PTD protein transduction domain
  • the invention may provide an agent or construct comprising (i) an oligopeptidic compound comprising an amino acid sequence as set forth in SEQ ID NO: 2 (RLVPK), and (ii) a cell penetrating sequence (more particularly a cell penetrating peptide).
  • CPP Cell penetrating peptide
  • CPPs are not characterized by a single structural or functional motif
  • tools to identify CPPs are available and the skilled person can readily determine whether a peptide sequence may function to facilitate the uptake of the peptide of which it forms a domain, i.e. whether a peptide sequence may function as an uptake (import) peptide, e.g. a CPP.
  • a peptide sequence may function as an uptake (import) peptide, e.g. a CPP.
  • Hansen et al Predicting cell- penetrating peptides, Advanced Drug Delivery Reviews, 2008, 60, pp.
  • the methodology works by computing z-scores of a candidate peptide as based on a numerical value and an associate range. If the z-scores fall within the range of known CPP z-scores, the examined peptides are classified as CPPs. The method was shown to have high accuracy (about 95% prediction of known CPPs). Additional methods for the prediction of CPPs have been developed subsequently (see e.g. Sanders et al., Prediction of Cell Penetrating Peptides by Support Vector Machines, PLOS Computational Biology, 201 1 , 7(7), pp.
  • CPPSite a curated database of cell penetrating peptides, Database, 2012, Article ID bas015 and http://crdd.osdd.net/raghava/cppsite/index.php, both herein incorporated by reference.
  • any suitable CPP may find utility in the invention and, as discussed below, a variety of CPPs have already been identified and tested and could form the basis for determining and identifying new CPPs.
  • CPPs may be derived from naturally-occurring proteins which are able to translocate across cell membranes such as the Drosophila homeobox protein Antennapedia (a transcriptional factor), viral proteins such as the HIV-1
  • transcriptional factor TAT and the capsid protein VP22 from HSV-1 may be synthetically-derived, e.g. from chimeric proteins or synthetic polypeptides such as polyarginine.
  • TAT and the capsid protein VP22 from HSV-1 may be synthetically-derived, e.g. from chimeric proteins or synthetic polypeptides such as polyarginine.
  • chimeric proteins or synthetic polypeptides such as polyarginine.
  • polyarginine polyarginine
  • FQNRRMKWKK (SEQ ID NO: 7)
  • RREKWKK (SEQ ID NO: 8)
  • KRMKWKK (SEQ ID NO: 10)
  • RRMKKWK (SEQ ID NO: 17) (using standard single amino acid notation,
  • Pegelin RGGRLSYSRRRFSTSTGR Rouselle, C. et
  • HIV-TAT GRKKRRQRRRPPQ (SEQ ID NO: 20) Vives E.J Biol,
  • VKRGLKLRHVRPRVTRMDV (SEQ ID NO: 30) Coupade peptides SRRARRSPRHLGSG * (SEQ ID NO: 31 ) (2005)
  • Antennapedia-derived CPPs represent a class of particular interest, based around the 16 amino acid Penetratin sequence as shown in Table 1 , which corresponds to the third loop of antennapedia protein and was shown to be responsible for translocation of the protein.
  • Penetratin has been extensively developed as a delivery vehicle, including particularly for pharmaceutical use, and a wide range of Penetratin derivatives and modified sequences have been proposed and described. Reference may be made in particular to WO 91/1891 , WO 00/1417, WO 00/29427, WO 2004/069279 and US 6,080,724 (herein incorporated by reference).
  • the 16 amino acid sequence of Penetratin may be modified and/or truncated, or the peptide may be chemically-modified or retro-, inverso- or retro- inverso analogues may be made whilst retaining cell-penetrating activity.
  • HIV-TAT sequence Another group of cell penetrating peptides which may advantageously be used are based on the HIV-TAT sequence and HIV-TAT and fragments thereof represent a preferred class of CPPs for use according to the present invention.
  • TAT-based CPPs are described in US 5,656,122 (herein incorporated by reference).
  • An exemplary HIV-TAT peptide as used in the Examples below is RKKRRQRRR (SEQ ID NO: 36) but it will readily be appreciated that longer or shorter TAT fragments may be used.
  • CPPs may be identified by particular features, such as for example peptides which are amphipathic and net positively charged.
  • Other groups of CPPs may have a structure exhibiting high a- helical content.
  • Another group may be peptides characterised by a high content of basic amino acids.
  • CPPs may thus be or may comprise oligomers of basic amino acids such as arginine e.g. 5 to 20, 6 to 15 or 6 to 12 R residues e.g. R 7 (SEQ ID NO: 35) , R 8 (SEQ ID NO: 37) or Rn (SEQ ID NO: 38) or QSR 8 (SEQ ID NO: 39).
  • the domain that facilitates the uptake of the oligopeptidic compound may be defined as a peptide of 4-30 amino acids (e.g. 5-29, 6-28, 7-27, 8-26, 9-25 etc. amino acids), wherein at least 4 amino acids (e.g. at least 5, 6, 7, 8, 9, 10 or 1 1 amino acids, e.g. 4-20, 5-19, 6-18, 7-17, 8- 16, 9-15, 10-14, 1 1 -13 amino acids) are positively charged amino acids, preferably selected from K, R or H.
  • 4 amino acids e.g. at least 5, 6, 7, 8, 9, 10 or 1 1 amino acids, e.g. 4-20, 5-19, 6-18, 7-17, 8- 16, 9-15, 10-14, 1 1 -13 amino acids
  • Proline-rich amphipathic peptides are another class of CPP and such peptides characterised by the presence of pyrrolidine rings from prolines are described in Pujals et al. 2008 Advanced Drug Delivery Reviews 60, pages 473-484 (herein incorporated by reference).
  • CPPs include pVEC (Elmquist et al. 2003
  • CPPs include Chariot, based on the Pep-1 peptide
  • CPPs include the R41 , R8, M918 and YTA-4 peptides (SEQ ID NOs: 40-43, respectively) disclosed in Eriksson et al. 2013, Antimicrobial Agents and Chemotherapy, vol. 57(8), pp. 3704-3712 (incorporated herein by reference).
  • the CPPs may be cyclic peptides, such as those disclosed in Oh et al., 2014, Mol. Pharmaceutics, vol. 1 1 , pp. 3528-3536
  • the CPPs may be amphiphilic cyclic CPPs, particularly containing tryptophan and arginine residues.
  • the CPPs may be cyclic polyarginine peptides and may be modified by the addition of a fatty acyl moiety, e.g. octanoyl, dodecanoyl, hexadecanoyl, N- acetyl-L-tryptophanyl-12-aminododecanoyl etc.
  • Suitable cyclic CPPs for use in the invention are presented in SEQ ID NOs: 44-50.
  • novel or derivative CPP peptides may be designed and synthesized based on known or reported criteria (e.g. known CPP sequences or features such as basic amino acid content, ohelical content etc. as discussed above). Additionally, randomly-designed or other peptides may be screened for CPP activity, for example by coupling or attaching such a peptide containing a reporter molecule, e.g. a detectable label or tag such as a fluorescent tag to the desired cargo (e.g. an oligopeptidic compound as described herein) and testing to see if the construct is translocated across the cell membrane, for example by adding these peptides to live cells followed by examination of cellular import e.g. using confocal microscopy.
  • a reporter molecule e.g. a detectable label or tag such as a fluorescent tag
  • desired cargo e.g. an oligopeptidic compound as described herein
  • CPPs may also facilitate the uptake of peptides into prokaryotic cells. It is thought that the capacity of CPPs to function in prokaryotic cells is a result of their structural similarity to anti- bacterial peptides, e.g. short, cationic peptides with amphipathic properties.
  • the primary antibacterial activity of the peptides of the invention arises from the APIM motif rather than the presence of a CPP sequence. It may in some cases be observed that successful or efficient delivery may be dependent, or may vary depending, on the precise nature of the cargo (e.g. cargo peptide sequence) and/or the CPP used. It would be well within the routine skill of the person skilled in the art to determine optimum peptide sequences and combinations etc, and to test and/or modify cargo and/or CPP sequence or structure etc.
  • the skilled person will be aware of suitable cell penetrating peptide sequences that, based on the findings of the inventors, may facilitate the uptake of the oligopeptidic compound, but by way of example the sequences may include PenetratinTM, a 16-amino acid peptide corresponding to the third helix of the homeodomain of Antennapedia protein, R rich tags such as R6- Penetratin (in which arginine-residues were added to the N-terminus of Penetratin) and derivatives of the HIV Tat protein such as GRKKRRQRRRPPQQ (SEQ ID NO: 51 ).
  • PenetratinTM a 16-amino acid peptide corresponding to the third helix of the homeodomain of Antennapedia protein
  • R rich tags such as R6- Penetratin (in which arginine-residues were added to the N-terminus of Penetratin)
  • derivatives of the HIV Tat protein such as GR
  • the domain that facilitates the cellular uptake of the oligopeptidic compound is a CPP and may be selected from any one of:
  • an amphipathic class peptide selected from an amphipathic and net positively charged peptide, a proline-rich amphipathic peptide, a peptide based on the Pep-1 peptide and a peptide based on the MPG peptide;
  • the domain that facilitates the cellular uptake of the oligopeptidic compound is a CPP and may be selected from a sequence selected from any one of SEQ ID NOs: 3-874 or a functional fragment and/or derivative thereof.
  • the details and properties of the CPPs identified in SEQ ID NOs: 52-874 can be found at http://crdd.osdd.net/raghava/cppsite/index.php, CPPSite: A database of cell penetrating peptides (herein incorporated by reference).
  • the domain that facilitates the cellular uptake of the oligopeptidic compound is SEQ ID NO: 38.
  • the oligopeptidic compound also comprises one or more domains that provide a signal (target or transit) sequence.
  • the signal sequence may target the oligopeptidic compound to a specific cell type. Additionally or alternatively, in some embodiments the
  • oligopeptidic compound may comprise a signal peptide that is capable of localising the compound to a specific intracellular compartment, e.g. the nucleus.
  • the uptake (import) peptide e.g. CPP, may be sufficient to direct or localise the oligopeptidic compound to the appropriate cellular location.
  • the signal sequence or signal sequence domain may thus be viewed as any sequence which acts to localise (or is capable of localising), or alternatively put, to direct, translocate or transport (or is capable of directing, translocating or transporting), the oligopeptidic compound to any desired location e.g. to any desired cell type, e.g. prokaryotic, or subcellular location, e.g. nucleus.
  • the oligopeptidic compound (or constructs) of the invention and for use in the use and methods of the invention may comprise one or more signal sequences (i.e. one or more domains that function as signal sequences or are capable of functioning as signal sequences in some cell types), e.g. a signal peptide which directs the compound (or construct) into a particular sub-cellular compartment, such as the nucleus.
  • Nuclear localisation signals are again well known in the art and widely described in the literature. For instance, a searchable database of known and predicted NLSs is available, see e.g. Cokol et al (Finding nuclear localization signals, EMBO Reports, 2000, 1 (5), pp. 41 1 -415, herein incorporated by reference).
  • the PSORT II database is another database of known and predicted NLSs.
  • An NLS may vary in length and/or sequence and a wide range of specific NLS sequences have been described. In general, however, it has been found that peptides comprising positively charged amino acids (notably lysine (K), arginine (R) and/or histidine (H)) may function as an NLS.
  • An exemplary NLS may thus be a peptide of e.g. 4-20, more particularly 4-15, 4-12, 4-10 or 4-8 amino acids, wherein at least 4 amino acids (and more particularly at least 60, 70, 75, 80, 85, or 90% of the amino acid residues in the NLS peptide) are positively charged amino acids, preferably selected from K, R or H.
  • Such an exemplary NLS may for example have or comprise the sequence RKRH (SEQ ID NO: 875).
  • Nuclear localisation signals including both actual experimentally-determined and predicted or proposed NLS sequences, and strategies for identifying NLSs are also described in Lange et al., J. Biol. Chem. 2007, 282(8), 5101 -5105; Makkerh et al., Current Biology 1996, 6(8), 1025-1027; Leslie et al., Methods 2006, 39, 291 - 308; and Lusk et al. Nature Reviews MCB 2007, 8, 414-420 (all herein incorporated by reference).
  • a classical NLS consists of either one (monopartite) or two (bipartite) stretches of basic amino acids.
  • a monopartite NLS may be exemplified by the SV40 large T antigen NLS ( 126 PKKKRKV 132 [SEQ ID NO: 876]) and a bipartite NLS by the nucleoplasms NLS ( 155 KRPAATKKAGQAKKKK 170 TSEQ ID NO: 877]).
  • the monopartite NLS consensus sequence K-[K/R]-X-[K/R] (SEQ ID NO: 878) has been proposed and accordingly an NLS according to the present invention may in one embodiment comprise or consist of such a consensus sequence (where X is any amino acid).
  • a representative bipartite NLS according to the invention may have the sequence KR-[X] 5-2 o-KKKK (SEQ ID NO: 879), e.g. KR-X 10 -KKKK (SEQ ID NO: 880) (where X is any amino acid).
  • An alternative exemplary bipartite NLS may take the form RKRH-[X] 2- io-KK (SEQ ID NO: 881 )e.g. RKRH-X 2 -KK (SEQ ID NO: 882), for example RKRH-II-KK (SEQ ID NO: 883).
  • the oncoprotein c-myc NLS differs from classical NLSs in that only 3 of 9 amino acid residues are basic (PAAKRVKLD [SEQ ID NO: 884]), indicating that an NLS need not necessarily conform to the consensus or classical sequences given above.
  • Makkerh et al describe NLS sequences in which a cluster of basic amino acids (e.g. KKKK [SEQ ID NO: 885]) is flanked by neutral and acidic residues, for example PAAKKKKLD (SEQ ID NO: 886).
  • NLS sequences which may be given by way of example include: PKKKRKVL (SEQ ID NO: 887), KKKRK (SEQ ID NO: 888), KKKRVK (SEQ ID NO: 889), KKKRKVL (SEQ ID NO: 890) and RKKRKVL (SEQ ID NO: 891 ).
  • Any NLS which is a derivative of a known NLS e.g. the SV40, nucleoplasm ⁇ , UNG2 or c-myc NLS may be used.
  • a putative, proposed or predicted NLS sequence can be tested for NLS activity using principles and assays known and described in the art.
  • a candidate NLS sequence may be attached to the desired cargo (in this case an oligopeptidic compound as defined herein) and the construct may be provided with a detectable reporter molecule (e.g. a tag or label which may be visualised, for example a fluorescent label) and contacted with a test cell. Distribution of the construct in the cell may then be determined.
  • a detectable reporter molecule e.g. a tag or label which may be visualised, for example a fluorescent label
  • nuclear localisation sequences include the SV40 protein derivative KKKRK (SEQ ID NO: 888).
  • the oligopeptidic compound comprises a signal sequence (i.e. a domain comprising a signal peptide) that localizes or directs the oligopeptidic compound to a sub-cellular location (or is capable of localizing or directing the oligopeptidic compound to a sub-cellular location in some cell types), such as a NLS and may be selected from any one of:
  • the nuclear localisation signal sequence comprises a sequence selected from any one of SEQ ID NOs: 875-891 or a fragment and/or derivative thereof, preferably wherein said fragment and/or derivative comprises at least 4 positively charged amino acids, preferably selected from any of K, R or H.
  • an oligopeptidic compound or construct according to the present invention may comprise at least three domains, including (i) an amino acid sequence as set forth in SEQ ID NO: 2 (RLVPK), (ii) a linker domain, which may in some embodiments comprise a nuclear localisation signal sequence, and (iii) a peptide sequence domain that facilitates the cellular uptake of said compound or construct (i.e. an uptake/import peptide sequence domain, e.g. cell penetrating signal sequence domain).
  • RLVPK amino acid sequence as set forth in SEQ ID NO: 2
  • a linker domain which may in some embodiments comprise a nuclear localisation signal sequence
  • a peptide sequence domain that facilitates the cellular uptake of said compound or construct i.e. an uptake/import peptide sequence domain, e.g. cell penetrating signal sequence domain.
  • the separate elements or components (domains) of a construct according to the present invention may be contained or presented in any order, but preferably in the orders indicated above (e.g. SEQ ID NO: 2 (RLVPK)-CPP or SEQ ID NO: 2 (RLVPK)-linker-CPP).
  • SEQ ID NO: 2 is located at or towards the N-terminus of the peptide.
  • SEQ ID NO: 2 may be described as being N-terminal to the peptide sequence domain that facilitates the cellular uptake of said compound (e.g. the CPP) and optionally N-terminal to the linker sequence, if present.
  • the oligopeptidic compound comprises an amino acid sequence as set forth in SEQ ID NO: 2, a nuclear localisation signal sequence/linker sequence as set forth in SEQ ID NO: 888 and a cell penetrating signal sequence as set forth in SEQ ID NO: 38.
  • an oligopeptidic compound or construct according to the invention may contain more than one domain comprising an amino acid sequence as set forth in SEQ ID NO: 2.
  • an agent of the invention and for use in the uses and methods of the present invention may contain or encode an oligopeptidic compound comprising more than one amino acid sequence as set forth in SEQ ID NO: 2.
  • a construct or oligopeptidic compound may for example contain 1 -10, e.g. 1 -6, or 1 -4 or 1 -3 or one or two motifs, i.e. amino acid sequences as set forth in SEQ ID NO: 2.
  • such motifs may be spaced or located according to choice, e.g.
  • motif-motif-CPP motif-linker-motif-CPP
  • motif-linker-motif-CPP or motif-linker-motif-motif-CPP
  • motif-motif-linker-CPP etc.
  • a “fragment” may comprise at least 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98 or 99% of the amino acids of the sequence from which it is derived.
  • Said fragment may be obtained from a central or N-terminal or C- terminal portions of the sequence. Whilst the size of the fragment will depend on the size of the original sequence, in some embodiments the fragments may be 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15 or more amino acid residues shorter than the sequence from which it is derived, e.g. 1 -10, 2-9, 3-8, 4-7 amino acid residues shorter than the sequence from which it is derived.
  • a "derivative" of a sequence is at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98 or 99% identical to the sequence to which it is compared.
  • Sequence identity may be determined by, e.g. using the SWISS-PROT protein sequence databank using FASTA pep-cmp with a variable pamfactor, and gap creation penalty set at 12.0 and gap extension penalty set at 4.0, and a window of 2 amino acids. Preferably said comparison is made over the full length of the sequence, but may be made over a smaller window of comparison, e.g. less than 200, 100, 50, 20 or 10 contiguous amino acids.
  • sequence identity related polypeptides i.e. derivatives
  • amino acids amino acids which are set forth in the recited SEQ ID NOs.
  • the peptides with sequences as set forth in the SEQ ID NOs. may be modified without affecting the sequence of the polypeptide as described below.
  • fragments as described herein may be functional equivalents. Preferably these fragments satisfy the identity (relative to a
  • the peptide may show some reduced efficacy in performing the function relative to the parent molecule (i.e. the molecule from which it was derived, e.g. by amino acid substitution), but preferably is as efficient or is more efficient.
  • functional equivalence may relate to a peptide which is effective in localizing or directing the oligopeptidic compound to the cell type or cellular location, e.g. to facilitate to the uptake of the peptide as described above. This may be tested by comparison of the effects of the derivative peptide relative to the peptide from which it is derived in a qualitative or quantitative manner, e.g. by performing the in vitro analyses described above. Where quantitative results are possible, the derivative is at least 30, 50, 70 or 90% as effective as the parent peptide.
  • Functionally-equivalent peptides which are related to or derived from the parent peptide, may be obtained by modifying the parent amino acid sequence by single or multiple amino acid substitution, addition and/or deletion (providing they satisfy the above-mentioned sequence identity requirements), but without destroying the molecule's function.
  • the parent sequence has less than 20 substitutions, additions or deletions, e.g. less than 10, 5, 4, 3, 2, or 1 such modifications.
  • Such peptides may be encoded by "functionally-equivalent nucleic acid molecules" which may be generated by appropriate substitution, addition and/or deletion of one or more bases.
  • domains (which may be viewed as components, elements or separate parts) of an oligopeptidic compound or construct of the invention as described herein may be attached or linked to one another in any desired or convenient way according to techniques well known in the art.
  • the domains may be linked or conjugated chemically, e.g. using known chemical coupling technologies or the compound or constructs may be formed as a single whole using genetic
  • engineering techniques e.g. techniques for forming fusion proteins, or they may simply be synthesized as a whole, e.g. using peptide synthesis techniques.
  • the domains may be linked directly to each other or they may be linked indirectly by means of one or more linker (or spacer) sequences.
  • a linker sequence may interspace or separate two or more individual domains (i.e. parts, e.g. or separate motif elements) in an oligopeptidic construct or compound.
  • the precise nature of the linker sequence is not critical and it may be of variable length and/or sequence, for example it may have 0-40, more particularly 0-20, 0-15, 0-12,
  • linker sequence if present, may have 1 -15, 1 -12, 1 -10,
  • residues may for example be any amino acid, e.g. a neutral amino acid, or an aliphatic amino acid, or alternatively they may be hydrophobic, or polar or charged or structure- forming e.g. proline.
  • linker sequences have been shown to be of use, including short (e.g. 1 -6) sequences of neutral and/or aliphatic amino acids.
  • Exemplary linker sequences thus include any single amino acid residue, e.g. A, I, L, V, G, R, Q, T, or W, or a di-, tri- tetra- penta- or hexa-peptide composed of such residues.
  • linkers may be mentioned I, II, IL, R, W, WW, WWW, RIL, RIW, GAQ, GAW, VAT, IILVI (SEQ ID NO: 892), IILVIII (SEQ ID NO: 893) etc.
  • linkers between different domains may be the same or different.
  • the linker may comprise or consist of an NLS.
  • an NLS when present, may function both as a signal peptide and a linker.
  • the oligopeptidic compound may comprise a signal peptide (e.g. an NLS) and a linker.
  • Representative compounds (or more particularly constructs) of the invention and for use in the methods and uses of the invention include:
  • MDRLVPKGAQPKKKRKVLRQIKIWFQNRRMKWKK (SEQ ID NO: 897), MDRLVPKGAWKKKRVKIIRKKRRQRRRK (SEQ ID NO: 898),
  • MDRLVPKRIWKKKRKIIRQIKIWFQNRRMKWKK SEQ ID NO: 905
  • MDRLVPKGAWRKRHIIKKRKKRRQRRRK SEQ ID NO: 906
  • the oligopeptidic compound comprises a sequence as set forth in SEQ ID NO: 894.
  • the oligopeptidic compounds shown above comprise N-terminal amino acids that do not form part of the domain (SEQ ID NO: 2) that is essential for the compounds to have activity in the methods and uses of the invention, i.e. an "MD" sequence.
  • Some of the peptides may also comprise N-terminal modification, e.g. acetyl groups. These additional amino acids and modifications may facilitate the production of the oligopeptidic compounds, e.g. in vitro or in vivo, and/or help to protect the compounds from degradation in vivo. It will be evident that the oligopeptidic compounds do not require these additional amino acids or modifications for their activity.
  • the oligopeptidic compound may comprise an N-terminal sequence, e.g. a sequence at the N-terminus that does not comprise a domain defined above, e.g. a so-called N-terminal flanking sequence.
  • the oligopeptidic compound may comprise a C-terminal sequence, e.g. a sequence at the C-terminus that does not comprise a domain defined above, e.g. a so-called C-terminal flanking sequence.
  • the oligopeptidic compound may comprise an N-terminal and C- terminal flanking sequence.
  • the oligopeptidic compound of the invention may be in the form of a salt.
  • the oligopeptidic compound may be in the form of an acidic or basic salt.
  • the oligopeptidic compound is in a neutral salt form.
  • the oligopeptidic compound may be in the form of an acetate salt or derivative thereof, e.g. trichloroacetate (TCA),
  • the oligopeptidic compound may be stabilized by preparing it in the form of a salt, e.g. an acetate salt.
  • a flanking sequence may comprise from about 1 -150 amino acids, such as
  • flanking sequence may comprise 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24 or 25 amino acids, e.g. 1 -40, 2-39, 3-38, 4-37, 5-36, 6-35, 7- 34, 8-33, 9-32, 10-31 , 1 1 -30, 12-29, 13-28, 14-27, 15-26 amino acids or any combination thereof.
  • Oligopeptidic compounds having sequences as set out in SEQ ID NOs. 894- 913 comprise separate domains (i.e. components) making up the constructs (i.e. motif-containing sequence, linker/NLS, CPP, etc.)
  • SEQ ID NOs. 894-913 represent constructs comprising at least one motif-containing sequence (SEQ ID NO: 2), a linker/NLS and a CPP.
  • Linker sequences based on the NLS sequence from SV40 are used, and the CPP sequences are based on
  • Penetratin HIV-TAT or an R-rich peptide.
  • K stands for lysine (Lys)
  • I stands for isoleucine (lie) and so on.
  • the oligopeptidic compound and more particularly domains in the
  • oligopeptidic compound may comprise non-conventional or non-standard amino acids.
  • the oligopeptidic compound may comprise one or more, e.g. at least 1 , 2, 3, 4 or 5 non-conventional amino acids, i.e. amino acids which possess a side chain that is not coded for by the standard genetic code, termed herein "non-coded amino acids" (see e.g. Table 2).
  • amino acids which are formed through metabolic processes such as ornithine or taurine, and/or artificially modified amino acids such as 9/-/-fluoren-9- ylmethoxycarbonyl (Fmoc), (tert)-(B)utyl (o)xy (c)arbonyl (Boc), 2,2,5,7,8- pentamethylchroman-6-sulphonyl (Pmc) protected amino acids, or amino acids having the benzyloxy-carbonyl (Z) group.
  • non-coded amino acids are present, they are not located within the motif (SEQ ID NO: 2).
  • non-coded amino acids are present in more than one domain of the oligopeptidic compound.
  • In vitro and/or in vivo stability of the oligopeptidic compound may be improved or enhanced through the use of stabilising or protecting means known in the art, for example the addition of protecting or stabilising groups, incorporation of amino acid derivatives or analogues or chemical modification of amino acids.
  • Such protecting or stabilising groups may for example be added at the N and/or C-terminus.
  • An example of such a group is an acetyl group and other protecting groups or groups which might stabilise a peptide are known in the art.
  • the oligopeptidic compounds of the invention will typically comprise only amino acids having the L-configuration, but one or more amino acids having the D configuration may be present.
  • the oligopeptidic compound contains at least 1 , 2, 3, 4 or 5 D-amino acids and they are preferably found in the motif (SEQ ID NO: 2), but in another embodiment, D-amino acids are present only outside of the motif. In a still further embodiment, D-amino acids may be found in more than one domain of the oligopeptidic compound.
  • the oligopeptidic compound may be linear or cyclic, preferably linear.
  • oligopeptidic compound is meant a compound which is composed of amino acids or equivalent subunits, which are linked together by peptide or equivalent bonds.
  • oligopeptidic compound includes peptides and peptidomimetics.
  • equivalent subunit is meant a subunit which is structurally and functionally similar to an amino acid.
  • the backbone moiety of the subunit may differ from a standard amino acid, e.g. it may incorporate one or more nitrogen atoms instead of one or more carbon atoms.
  • the subunit comprises a standard amino acid backbone, i.e. the backbone of a standard or coded amino acid.
  • the subunit is an amino acid.
  • the amino acid subunit may comprise a non-standard (non-coded) R-group.
  • peptidomimetic is meant a compound which is functionally equivalent or similar to a peptide and which can adopt a three-dimensional structure similar to its peptide counterparts, but which is not solely composed of amino acids linked by peptide bonds.
  • a preferred class of peptidomimetics are peptoids, i.e. /V-substituted glycines. Peptoids are closely related to their natural peptide counterparts, but they differ chemically in that their side chains are appended to nitrogen atoms along the molecule's backbone, rather than to the ocarbons as they are in amino acids.
  • Peptidomimetics particularly non-peptidic molecules may be generated through various processes, including conformational-based drug design, screening, focused library design and classical medicinal chemistry. Not only may oligomers of unnatural amino acids or other organic building blocks be used, but also
  • carbohydrates, heterocyclic or macrocyclic compounds or any organic molecule that comprises structural elements and conformation that provides a molecular electrostatic surface that mimics the same properties of the 3-dimensional conformation of the peptide may be used by methods known in the art.
  • peptidomimetics may bear little or no resemblance to a peptide backbone.
  • Peptidomimetics may comprise an entirely synthetic non-peptide form (e.g. based on a carbohydrate backbone with appropriate substituents) or may retain one or more elements of the peptide on which it is based, e.g. by derivatizing one or more amino acids or replacing one or more amino acids with alternative non-peptide components.
  • Peptide-like templates include pseudopeptides and cyclic peptides. Structural elements considered redundant for the function of the peptide may be minimized to retain a scaffold function only or removed where appropriate.
  • peptidomimetics retain one or more peptide elements, i.e. more than one amino acid, although such amino acids may be replaced with a non-standard or structural analogue thereof.
  • Amino acids retained in the sequences may also be derivatised or modified (e.g. labelled, glycosylated or methylated) as long as the functional properties of the oligopeptidic compound are retained.
  • the peptidomimetics are referred to as being "derivable from" a certain polypeptide sequence. By this it is meant that the peptidomimetic is designed with reference to the peptide sequence defined above, such that it retains the structural features of the peptide which are essential for its function.
  • This may be the particular side chains of the peptide, or hydrogen bonding potential of the structure.
  • Such features may be provided by non-peptide components or one or more of the amino acid residues or the bonds linking said amino acid residues of the polypeptide may be modified so as to improve certain functions of the peptide such as stability or protease resistance, while retaining the structural features of the peptide which are essential for its function.
  • non-standard or structural analogue amino acids which may be used are D amino acids, amide isosteres (such as N-methyl amide, retro-inverse amide, thioamide, thioester, phosphonate, ketomethylene, hydroxymethylene, fluorovinyl, (E)-vinyl, methyleneamino, methylenethio or alkane), L-N methylamino acids, D-a methylamino acids, D-N-methylamino acids. Examples of non- conventional, i.e. non-coded, amino acids are listed in Table 2.
  • Non-conventional Code Non-conventional Code amino acid amino acid a-aminobutyric acid Abu L-N-methylalanine Nmala a-amino-a-methylbutyrate Mgabu L-N-methylarginine Nmarg aminocyclopropane- Cpro L-N-methylasparagine Nmasn carboxylate L-N-methylaspartic acid Nmasp aminoisobutyric acid Aib L-N-methylcysteine Nmcys aminonorbornyl- Norb L-N-methylglutamine Nmgln carboxylate L-N-methylglutamic acid Nmglu cyclohexylalanine Chexa L-N-methylhistidine Nmhis cyclopentylalanine Cpen L-N-methylisolleucine Nmile
  • the oligopeptidic compound is a peptide.
  • the oligopeptidic compound is a peptide consisting of L-amino acids.
  • the oligopeptidic compound is a peptide consisting of standard or coded L-amino acids.
  • the oligopeptidic compound may comprise nonstandard amino acids.
  • the oligopeptidic compound may incorporate di-amino acids and/or ⁇ -amino acids.
  • at least the motif domain (SEQ ID NO: 2), consists of oarmino acids.
  • the oligopeptidic compound i.e. all domains and optionally all flanking sequences, consists of oarmino acids.
  • the oligopeptidic compound defined herein comprises more than 5 subunits, but the length of the construct will depend on the size of the uptake peptide sequence and on the number and size of other domains, e.g. linker domains, flanking sequences etc, if present.
  • the prefix "oligo” is used to designate a relatively small number of subunits such as amino acids, i.e. less than 200, preferably less than 150, 100, 90, 80, 70, 60 or 50 subunits.
  • the oligopeptidic compound of the invention may thus comprise more than 5 but no more than 200 subunits. Preferably, it comprises at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24 or 25 subunits.
  • subunit ranges thus include 12- 50, 12-45, 12-40, 12-35, 12-30, 12-25, 12-22, 12-20, 12-18 etc, 12-30 and 12-40 being preferred. Further representative subunit ranges include 20-50, 21 -45, 22-40, 23-35, 24-30, e.g. 25, 26, 27, 28, 29 or 30.
  • the nature of the subunits of the oligopeptidic compound outside of the motif domain (SEQ ID NO: 2) and the uptake peptide sequence is not critical, so the subunits outside of the motif may for example be alanine residues or any other suitable residues.
  • Peptidomimetics typically have a longer half life within a patient's body, so they may be preferred in embodiments where a longer lasting effect is desired. This can help reduce the frequency at which the composition has to be re- administered. Furthermore, peptidomimetics may be particularly useful in the in vitro methods described herein. However, for bio-safety reasons a shorter half life may be preferred in other embodiments; in those embodiments peptides are preferred.
  • the oligopeptidic compound may form part of a larger unit, e.g. it may be fused to a polypeptide to form a recombinant fusion protein or attached to a scaffold to form a peptide aptamer.
  • fusion proteins or aptamers incorporating the oligopeptidic compound may also find utility in the uses and methods of the invention, i.e. in some embodiments the agent may be a fusion protein or aptamer comprising the oligopeptidic compound defined above.
  • compositions comprising the agent defined herein, e.g. comprising the oligopeptidic compound, fusion protein or aptamer, together with at least one pharmacologically acceptable carrier or excipient.
  • said composition may be provided for use in the uses and methods of the invention defined below.
  • a nucleic acid molecule encoding a peptide having or comprising (e.g. of) SEQ ID NO: 2 is provided for use in the methods and uses of the invention.
  • the agent or composition for use in the uses and methods of the invention may be a nucleic acid molecule encoding a peptide having or comprising (e.g. of) SEQ ID NO: 2.
  • the nucleic acid molecule may not need to encode all of the domains of the oligopeptidic compound described above, e.g. the domain that facilitates the cellular uptake of the peptide.
  • the nucleic acid molecule may be delivered into the cell by another mechanism, e.g. via a liposome.
  • the invention provides a nucleic acid molecule encoding an oligopeptidic compound or construct (e.g. a peptide) as defined above, comprising an amino acid sequence as set forth in SEQ ID NO: 2 and a peptide sequence (domain) that facilitates the uptake of said peptide. Also provided is the complement of such a nucleic acid molecule for use in the uses and methods of the invention. Thus, in some embodiments the nucleic acid molecule may also encode one or more linker and/or signal sequences, as defined above.
  • the nucleic acid molecule of the invention comprises at least 15
  • nucleotides preferably at least 36 nucleotides, and preferably no more than 800 nucleotides, more preferably no more than 700, 650, 600, 550, 500, 450, 400, 350, 300, 250, 200, 150, 100, 75 or 50 nucleotides.
  • the nucleic acid molecule is preferably an isolated or synthetic molecule.
  • a further aspect of the invention relates to a vector comprising a nucleic acid molecule as defined herein for use in the uses and methods defined below.
  • the vector comprises a promoter sequence (e.g. a heterologous sequence) operably linked to the sequence encoding a peptide as defined above.
  • the vector may also contain further elements typically found in a vector such as an origin of replication, a selectable marker such as antibiotic resistance, and/or a multiple cloning site.
  • the vector may further be an expression vector, and may comprise further elements, e.g. transcriptional and/or translational control or regulatory elements for expression of the nucleic acid molecules.
  • control elements e.g. promoters, ribosome binding sites, enhancers, terminators etc. are well known and widely described in the art.
  • the vector may for example be a plasmid or a viral genome (or part thereof), preferably the viral gemone is from a virus selected from a retrovirus, an adenovirus and an adenovirus-associated virus.
  • the vector may be a viral genome (or part thereof) from a virus capable of infecting a bacterium such as a bacteriophage.
  • the vector may be administered in the form of a virus comprising a vector containing a nucleic acid molecule encoding an oligopeptidic compound described above.
  • the vector may be a virus.
  • the invention provides a composition (e.g. a pharmaceutical composition) comprising an agent as defined herein and its use in the methods and uses of the invention.
  • said composition e.g. a pharmaceutical composition
  • said composition may comprise an oligopeptidic compound (including a fusion protein or aptamer) and/or nucleic acid molecule as defined herein and/or a vector as defined herein, together with at least one pharmacologically (or pharmaceutically) acceptable carrier or excipient.
  • the excipient may include any excipients known in the art, for example any carrier or diluent or any other ingredient or agent such as buffer, antioxidant, chelator, binder, coating, disintegrant, filler, flavour, colour, glidant, lubricant, preservative, sorbent and/or sweetener etc.
  • any carrier or diluent or any other ingredient or agent such as buffer, antioxidant, chelator, binder, coating, disintegrant, filler, flavour, colour, glidant, lubricant, preservative, sorbent and/or sweetener etc.
  • the excipient may be selected from, for example, lactic acid, dextrose, sodium metabisulfate, benzyl alcohol, polyethylene glycol, propylene glycol, microcrystalline cellulose, lactose, starch, chitosan, pregelatinized starch, calcium carbonate, calcium sulfate, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, powdered cellulose, sodium chloride, sorbitol and/or talc.
  • the pharmaceutical composition may be provided in any form known in the art, for example as a tablet, capsule, coated tablet, liquid, suspension, tab, sachet, implant, inhalant, powder, pellet, emulsion, lyophilisate, effervescent, spray, salve, emulsion, balm, plaster or any mixtures thereof. It may be provided e.g. as a gastric fluid-resistant preparation and/or in sustained action form. It may be a form suitable for oral, parenteral, topical, rectal, genital, subcutaneous, transurethral,
  • the composition preferably may be formulated for topical administration, e.g. for the treatment or prevention of a bacterial infection in a wound, including a surgical wound.
  • the pharmaceutical composition may be in a form suitable for liposomal administration, so preferably liposomes containing the pharmaceutical composition are provided.
  • liposomes it may not be necessary to include a further excipient, so in a further embodiment the invention also provides liposomes containing an agent, e.g. oligopeptidic compound, as defined herein, and theiruse in the methods and uses of the invention.
  • treatment refers broadly to any effect or step (or intervention) beneficial in the management of a clinical condition or disorder and thus includes both therapeutic and prophylactic treatments.
  • Treatment may include reducing, alleviating, ameliorating, slowing the development of, or eliminating the condition or one or more symptoms thereof, which is being treated, relative to the condition or symptom prior to the treatment, or in any way improving the clinical status of the subject.
  • a treatment may include any clinical step or intervention which contributes to, or is a part of, a treatment programme or regimen.
  • a prophylactic treatment may include delaying, limiting, reducing or preventing the condition or the onset of the condition, or one or more symptoms thereof, for example relative to the condition or symptom prior to the prophylactic treatment.
  • Prophylaxis thus explicitly includes both absolute prevention of occurrence or development of the condition, or symptom thereof, and any delay in the onset or development of the condition or symptom, or reduction or limitation on the development or progression of the condition or symptom.
  • treatment includes killing, inhibiting or slowing the growth of bacterial cells, or the increase in size of a body or population of bacterialcells, reducing bacterial cell number or preventing the spread of bacterial cells (e.g. to another anatomic site), reducing the size of a bacterial cell colony or infection site etc.
  • treatment does not necessarily imply the cure or complete abolition or elimination of bacterial cell growth, or growth of bacterial cells.
  • inhibitor is used broadly to include any reduction or decrease in bacterial cell growth as well as the prevention or abolition of bacterial cell growth. “Inhibition” thus includes the reduction or prevention of bacterial cell growth, e.g. including reducing the rate of cell growth. This may be determined by any appropriate or convenient means, such as determining or assessing cell number, cell viability and/or cell death etc., as may be determined by techniques well known in the art.
  • “Growth” of bacterial cells as referred to herein is also used broadly to include any aspect of bacterial cell growth, including in particular the proliferation (i.e. increase in number) of bacterial cells.
  • the agents as defined herein may thus be used in the treatment or prevention of any bacterial infection, which may be a disease or condition (used broadly herein to include any disorder or any clinical situation) which is responsive to reduction of bacterial cell growth (particularly bacterial cell proliferation).
  • the agents accordingly find utility in any therapy (or treatment) which targets bacterial cell growth (or proliferation).
  • the agents may be used in any therapeutic application in which it desirable or advantageous to inhibit bacterial cell proliferation.
  • a "bacterial infection” may be defined as any atypical, unwanted, undesirable, excessive and/or harmful infection and includes a "bacterial infectious disease” and may be defined as a disease, condition or disorder caused by the invasion of a subject, e.g. one or more organs or tissues of said subject, by one or more disease-causing bacteria and their subsequent multiplication.
  • an infection or infectious disease may be characterised by the reaction of the subject (e.g. organ or tissues of said subject) to said organisms and, in some cases, to the toxins produced by said organisms.
  • a bacterial infection or bacterial infectious disease may be local or systemic.
  • a bacterial infection may be any bacterial infectioncaused by a bacterium.
  • the bacteria may be a gram positive or gram negative, or gram test non-responsive. They may be aerobic or anaerobic bacteria.
  • the bacteria may be from any of the genus Acinetobacter, Bacillus, Burkholderia, Chlamydia, Clostridium, Helicobacter, Staphylococcus, Streptococcus, Pseudomonas, Legionella, Listeria, Mycobacterium, Proteus, Klebsiella, Fusobacterium or other enteric or coliform bacteria.
  • the bacterialinfection or bacterialinfectious disease may be caused by a gram-positive bacterium such as, M. tuberculosis, M. bovis, M. typhimurium, M. bovis strain BCG, BCG substrains, M. avium, M. intraceiiuiare, M. africanum, M. kansasii, M. marinum, M. ulcerans, M. avium subspecies
  • a gram-positive bacterium such as, M. tuberculosis, M. bovis, M. typhimurium, M. bovis strain BCG, BCG substrains, M. avium, M. intraceiiuiare, M. africanum, M. kansasii, M. marinum, M. ulcerans, M. avium subspecies
  • Staphylococcus equi Streptococcus pyogenes, Streptococcus agalactiae, Listeria monocytogenes, Listeria ivanovii, Bacillus anthracis, B. subtilis, Nocardia asteroides, Actinomyces israelii, Propionibacterium acnes, and Enterococcus species.
  • the bacterialinfection or bacterialinfectious disease may be caused by a gram-negative bacterium such as Clostridium tetani,
  • Clostridium perfringens Clostridium botulinum, Pseudomonas aeruginosa, Vibrio cholerae, Actinobacillus pleuropneumoniae, Pasteurella haemolytica, Pasteurella multocida, Legionella pneumophila, Salmonella typhi, Brucella abortus, Chlamydi trachomatis, Chlamydia psittaci, Coxiella burnetii, Escherichia coli, Neiserria meningitidis, Neiserria gonorrhea, Haemophilus influenzae, Haemophilus ducreyi, Yersinia pestis, Yersinia enterolitica, Escherichia coli, E.
  • the bacterial infection or bacterial infectious disease may be caused by a bacterium is selected from the following genera:
  • Achromobacter Acinetobacter, Actinobacillus, Aeromonas, Agrobacterium, Alcaligenes, Alteromonas, Bacteroides, Bartonella, Borrelia, Bordetella, Brucella, Burkholderia, Campylobacter, Cardiobacterium, Chlamydia, Chlamydophila,
  • Chromobacterium Chyseobacterium, Chryseomonas, Citrobacter, Clostridium, Comamonas, Corynebacterium, Coxiella, Cryptobacterium, Edwardsiella, Eikenella, Enterobacter, Enterococcus, Erwinia, Helicobacter, Kingella, Klebsiella,
  • the bacterium is a MDR bacterium.
  • the MDR bacterium is a Methicillin-resistant
  • MRSA Staphylococcus aureus
  • MRSA infections are caused by strains of Staphylococcus aureus that have become resistant to the antibiotics commonly used to treat ordinary Staphylococcus aureus infections.
  • HA-MRSA infections occur in people who have been in hospitals or other health care settings, such as nursing homes and dialysis centres, where it is known as health care-associated MRSA (HA-MRSA).
  • HA-MRSA infections typically are associated with invasive procedures such as surgery or the use of devices, such as intravenous tubing or artificial joints.
  • MRSA infections may also occur in the wider community, i.e. among healthy people; this form of MRSA infection, community-associated MRSA (CA-MRSA), often begins as a painful skin boil. It is spread by skin-to-skin contact and at-risk populations include groups that frequently are in contact with other people, such as high school wrestlers, child care workers and people who live in crowded conditions.
  • CA-MRSA community-associated MRSA
  • strains of MRSA have been identified and any strain of MRSA may be treated using the agents, compositions and methods of the invention. Particular strains are described below and identified in WO 2010/139957 (incorporated herein by reference) and may be viewed as preferred strains to be treated according to the present invention.
  • MRSA 1021 b is resistant to penicillin, clindamycin, gentamycin, fusidic acid erythromycin, trimethoprin, sulphamethoxazole, cefoxitin, ciprofloxacin, and fosphomycin glucose 6 phosphate.
  • MRSA 1 141 b is resistant to penicillin, clindamycin, fusidic acid,
  • MRSA 1 108 is resistant to penicillin, fusidic acid, trimethoprin, cefoxitin, rifampicin and ciprofloxacin.
  • MRSA 1047 is resistant to penicillin, fusidic acid, erythromycin, trimethoprin, cefoxitin, ciprofloxacin, mupirocin, chloramphenicol, and fosphomycin glucose 6 phosphate.
  • MRSA 1040 is resistant to penicillin, gentamycin, fusidic acid, erythromycin, trimethoprin, sulphamethoxazole, tetracycline, cefoxitin, ciprofloxacin and mupirocin.
  • MRSA 1096 is resistant to penicillin, gentamycin, erythromycin, trimethoprin, sulphamethoxazole, cefoxitin and ciprofloxacin.
  • Staphylococcus aureus ATCC-43300 is resistant to methicillin and oxacillin.
  • strains to be treated according to the present invention are MRSA 1040 and/or MRSA 1096.
  • an MRSA infection may be treated using an agent or composition of the invention in combination with an antibiotic.
  • the antibiotic is a macrolide antibiotic, such as Azithromycin, Erythromycin, Clarithromycin, Telithromycin, Carbomycin A, Josamycin,
  • the macrolide antibiotic is Azithromycin or Erythromycin.
  • the MDR bacterium is an Enterococcus faecium bacterium.
  • the MDR bacterial infection is an Enterococcus faecium infection.
  • An example of an MDR strain of Enterococcus faecium is Enterococcus faecium CCUG 37832 (TO-3).
  • Enterococcus faecium is commonly associated with endocarditis, urinary tract infections and infections in wounds. Enterococcus faecium may also cause meningitis, e.g. neonatal meningitis.
  • the subject to be treated according to the methods and uses of the invention has endocarditis, a urinary tract infection, an infected wound or meningitis, e.g. neonatal meningitis.
  • an Enterococcus faecium infection may be treated using an agent or composition of the invention in combination with an antibiotic.
  • the antibiotic is a DNA gyrase inhibitor, such as an aminocoumarin (e.g.
  • the antibiotic is 2,4-Diamin, S. methizol, S. methoxa, S. dimetho, Sulfaceta, Trimethoprim, Flumeq, Levoflox, Pruliflox, Metronid or Nitrofur.
  • a bacterial infection to be treated or prevented by the agent or composition of the invention may be in any tissue or organ of the subject to be treated, such as the lungs (including the respiratory tract), stomach, gastrointestinal tract (GIT), blood, skin (including wounds, such as surgical wounds), bladder (including the urinary tract), kidney, ear, eye, meninges etc.
  • the bacterial infection may be a respiratory infection, stomach infection, GIT infection, blood infection, skin infection, bladder infection, kidney infection, ear infection, eye infection, meningial infection etc.
  • a skin infection may include an infection of a mucosal membrane, such as the oral cavity, oesophagus or eye, e.g. cornea.
  • the infectious disease or a disease or condition exacerbated or caused by a bacterial infection may include any one of bacterial pneumonia, cystic fibrosis, gastric ulcers, bacterial meningitis, Legionellosis (Legionnaires' disease), Legionellosis (Pontiac fever), Pertussis (Whooping cough), Salmonellosis, Tuberculosis, sepsis etc.
  • the agent or composition as defined herein is used in combination with one or more additional active agents, e.g. an antibiotic, in order to enhance or complement the effect of agent or composition defined herein.
  • the additional active agent may be used to treat symptoms of the bacterialinfection or infectious disease, e.g. secondary symptoms, such agents may be, e.g. an anti-inflammatory compound, steroid (e.g. a corticosteroid) etc. and will be dependent on the nature of the disease, including the severity of the symptoms etc.
  • the agent as defined herein may be used alone, i.e. as the only active agent in a composition and/or medicament.
  • the additional active agent is an intracelluarly-active agent, i.e. it targets an intracellular process.
  • the additional active agent does not act at or on the cell wall or cell membrane, i.e. it does not exert its effect (e.g. antibiotic effect) by affecting the cell wall or cell membrane, e.g. by inhibiting cell wall synthesis or by permabilizing the cell.
  • anti-bacterial agent an agent which is capable of inhibiting or suppressing the growth and/or multiplication (replication/proliferation) of bacterial cells, such as an antibiotic agent. Included as anti-bacterial agents are any agents which may be indicated for an anti-bacterial application. Thus, included are agents used in anti-bacterial treatment protocols. However, agents that are not typically used for suppressing or inhibiting bacterialgrowth may find utility in combination with the agents defined herein, e.g. agents that generally have an effect on cell growth, such as
  • chemotherapeutic agents particularly DNA damaging agents.
  • the anti-bacterial agent is an antibiotic agent.
  • Suitable antibiotic agents include but are not limited to any one or more of Aminocoumarins (such as Novobiocin, Albamycin, Coumermycin and Clorobiocin), Aminoglycosides (such as Amikacin, Apramycin, Gentamicin, Kanamycin,
  • Neomycin Netilmicin, Tobramycin, Paromomycin and Spectinomycin
  • Ansamycins such as Geldanamycin, Herbimycin, Rifaximin and Streptomycin
  • Carbapenems such as Ertapenem, Doripenem, Cilastatin ('Imipenem') and Meropenem
  • Cephalosporins such as Cefadroxil, Cefazolin, Cefalothin ('Cefalotin'), Cefalexin, Cefaclor, Cefamandole, Cefoxitin, Cefprozil, Cefuroxime, Cefixime, Cefdinir,
  • Cefoperazone Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, Cefepime, Ceftaroline fosamil and Ceftobiprole
  • Glycopeptides such as Teicoplanin, Vancomycin and Telavancin
  • Lincosamides such as Clindamycin and Lincomycin
  • Lipopeptides such as Daptomycin
  • Macrolides such as
  • Nitrofurans such as Furazolidone and Nitrofurantoin
  • Oxazolidonones such as Linezolid, Posizolid, Radezolid and Torezolid
  • Penicillins such as
  • Ticarcillin/clavulanate Polyethers (such as Monensin), Polypeptides (such as Bacitracin, Colistin and Polymyxin B), Quinolones (such as Ciprofloxacin, Enoxacin, Gatifloxacin, Levofloxacin, Lomefloxacin, Moxifloxacin, Nalidixic acid, Norfloxacin, Ofloxacin, Trovafloxacin, Grepafloxacin, Sparfloxacin and Temafloxacin);
  • Sulfonamides such as Mafenide, Sulfacetamide, Sulfadiazine, Silver sulfadiazine, Sulfadimethoxine, Sulfamethizole, Sulfamethoxazole, Sulfanilimide, Sulfasalazine, Sulfisoxazole, Sulfamethoxazole (Co-trimoxazole, TMP-SMX, 'Trimethoprim') and Sulfonamidochrysoidine), Tetracyclines (such as Demeclocycline, Doxycycline, Minocycline, Oxytetracycline and Tetracycline) and Others (such as Clofazimine, Dapsone, Capreomycin, Cycloserine, Ethambutol, Ethionamide, Isoniazid, Pyrazinamide, Rifampicin ('Rifampin'), Rifabutin, Rifapentine,
  • Tetracyclines such as
  • additional active agents that may find utility in the invention may be grouped into different classes according to their mechanism of action and all of these classes are contemplated herein.
  • the additional active agent may be an alkylating agent, a cross-linking agent, an intercalating agent, a nucleotide analogue, an inhibitor of spindle formation, and/or an inhibitor of topoisomerase I and/or II.
  • Other types or classes of agent include anti-metabolites, plant alkaloids and terpenoids, or an anti-tumour antibiotic.
  • it is an alkylating agent.
  • Alkylating agents modify DNA by alkylating nucleosides, which leads to the prevention of correct DNA replication.
  • Nucleotide analogues become incorporated into DNA during replication and inhibit DNA synthesis.
  • Inhibitors of spindle formation disturb spindle formation, leading to the arrest of mitosis during metaphase.
  • Intercalating agents intercalate between DNA bases, thereby inhibiting DNA synthesis.
  • Inhibitors of topoisomerase I or II affect the torsion of DNA, thereby interfering with DNA replication.
  • Suitable additional active agents in the categories discussed above are known in the art, but by way of example MMS (Methyl methanesulphonate), actinomycin D, BCNU (carmustine), carboplatin, CCNU, Campothecin (CPT), cantharidin, Cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, Doxorubicin, DTIC, epirubicin, Etoposide, gefinitib, gemcitabine, ifosfamide and/or irinotecan, ionomycin, Melphalan, Methotrexate, Mitomycin C (MMC), mitozantronemercaptopurine, Oxaliplatin, Paclitaxel (taxol), PARP-1 inhibitor, taxotere, temozolomide (TZM), teniposide, topotecane, treosulfane vinorelbine, vincris
  • the additional active agent is present in the pharmaceutical composition, or administered to the subject, in its typical dose range.
  • a lower dose of the additional active agent may be used because the agent defined herein sensitises the bacterialcells to the additional active agents and so when used in combination with the agent of the invention, a lower dose of the additional active agent will have the same or a comparable therapeutic effect as a higher dose of the additional agent on its own.
  • a suitable dose for the agent or composition as defined herein may be defined as a dose that is sufficient, either alone or in combination with an additional active agent, to inhibit bacterial cell growth (e.g. in vivo or in vitro).
  • a suitable dose may be defined as a dose that is sufficient, either alone or in combination with an additional active agent to kill the majority of the bacterial cells causing, or associated with, the infection or infectious disease.
  • a suitable dose for the agent or composition as defined herein may be defined as a dose that is sufficient to sensitize a bacterium to an additional active agent, wherein contacting the bacterium with (e.g. treatment with or administration of) an agent and an additional active agent is sufficient to inhibit bacterial cell growth (e.g. in vivo or in vitro) and/or sufficient to kill the majority of the bacterial cells causing, or associated with, the infection or infectious disease.
  • the oligopeptidic compounds of the invention do not readily induce apoptosis in animal cells, i.e. the oligopeptidic compounds of the invention are not cytotoxic to animal (e.g. human) cells and accordingly, a wide variety of doses may be suitable in the methods and uses of the present invention.
  • the "majority of cells” may be defined as at least 50% of the bacterial cells, e.g. at least 60, 70, 80, 85, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99 or 100% of the cells, e.g. cells causing, or associated with, the infection or infectious disease.
  • the effective dose or amount of agent may depend on the characteristics of the peptide, e.g. its stability in vivo. Furthermore, effective dose or amount of the agent may depend upon the nature of the compound used (i.e. peptide, nucleic acid molecule etc), the mode of administration, the course of treatment, the age and weight of the patient, the medical indication, the body or body area to be treated, or the in vitro use, and may be varied or adjusted according to choice. Generally however, a low dose or amount may result in an active concentration range of about 0.01 , 0.05, 0.1 , 0.25, 0.5, 0.75, 1 .0, 1 .25, 1.50, 1 .75, 2.0, 3.0, 4.0, 5.0 to 10 ⁇ , e.g.
  • 0.01 to 10 ⁇ e.g. 0.05 to 7.5 ⁇ , such as 0.1 to 7.5 ⁇ , e.g. 0.5 to 5 ⁇ .
  • a high dose or amount may result in an active concentration range of about 1.0, 2.0, 3.0, 4.0, 5.0, 7.5, 10, 15, 20, 25, 30, 40 to 50 ⁇ , e.g. 1 .0 to 50 ⁇ , e.g. 2.0 to 40 ⁇ , such as 3.0 to 30 ⁇ , e.g. 5.0 to 25 ⁇ .
  • Said concentrations are determined by reference to the amount of the compound itself and thus appropriate allowances should be made to take into account the purity of the composition.
  • the subject is an animal (i.e. any human or non-human animal), preferably a mammal, most preferably a human.
  • the agent or composition of the invention as defined herein may be provided or administered via a product, device, implant or material to which the agent or composition has been applied, impregnated or chemically bonded.
  • the invention also provides a product, material, device or implant which is coated, impregnated or chemically bonded with an agent or composition as described herein.
  • the invention also extends to the use of such products, materials, devices or implants in the methods and uses as described herein.
  • the products, materials, devices or implants may be coated, impregnated or chemically bonded with an agent or composition as described herein to prevent or inhibit the formation of a bacterial biofilm.
  • the present invention also provides a method of preventing or inhibiting the formation of a bacterial biofilm on a product, material, device or implant, said method comprising:
  • bandages plasters (e.g. adhesive patches), gauze, surgical tape, cotton swabs or other absorbent materials, e.g. a puff, fleece, or sponge, supportive matrices or wound dressings may be coated, impregnated or chemically bonded with an agent or composition as described herein.
  • an agent or composition as described herein.
  • many compositions can be applied to the skin using dermal patches that are well described in the art, e.g. US 2008/0038300, US 2009/0043236, WO 2005/067499 and WO 2009/085302, which are incorporated herein by reference.
  • the material comprising the agent or composition as described herein may be in the form of a device that can be, e.g. worn by the subject to be treated.
  • the agent or composition as described herein may be applied, impregnated or chemically bonded onto a material or supportive matrix that forms all or part of a diaper, glove, sock etc.
  • the product or material is a bandage, plaster (e.g. adhesive patch), gauze, surgical tape, cotton swab, puff, fleece, sponge, supportive matrix, wound dressing, diaper, glove or sock.
  • the device or implant may be a medical or surgical device or implant.
  • the device or implant may be selected from, but is not limited to, a stent (e.g. coronary stent), ear tube (tympanostomy tube), artificial eye lens (i.e. a pseudophakos or intra-ocular lens), an orthopedic implant (e.g. screw, pin, plate or rod, such as for traumatic fracture repair or spinal fusion), an artificial bone (e.g. a spinal disc, hip, knee etc), a dental implant (e.g. an artificial tooth or part thereof), a cardiac device (e.g. an implantable cardioverter defibrillator, pacemaker etc.), a cosmetic implant (e.g. breast implant), intra-uterine device (IUD), a catheter (e.g. central venous or urinary catheter) or a prosthetic device.
  • a stent e.g. coronary stent
  • ear tube tympanostomy tube
  • artificial eye lens i.
  • the product or device may be a contact lens or contact lens storage case.
  • agent, composition, product, material, device or implant can be included in a container, pack, or dispenser together with instructions for administration and/or use.
  • Figure 1 shows (A) a graph showing the growth of E.coli in which the overexpression of an APIM peptide (RWLVK, SEQ ID NO: 914) is induced or not induced and demonstrates that the induction of an APIM peptide inhibits bacterial growth; (B) a graph showing the growth of E.coli in which the overexpression of a peptide containing the motif of the invention (RLVPK, SEQ ID NO: 2) is induced or not induced and demonstrates that the induction of a peptide of the invention inhibits bacterial growth; and (C) a graph showing the growth of E.coli in which the overexpression of a peptide that does not bind to PCNA with substantial affinity (RWLK, SEQ ID NO: 920) is induced or not induced and demonstrates that the induction of a peptide that does not interact with PCNA does not inhibit bacterial growth.
  • RWLK APIM peptide
  • Figure 2 shows graphs showing the growth of E.coli in the presence of 15 ⁇ of various peptides before (A) and after (B) the bacteria have been irradiated with UVC.
  • MD-RWLVK is SEQ ID NO: 916
  • MD-RLVPK is SEQ ID NO: 917
  • R1 1 is SEQ ID NO: 38.
  • Figure 3 shows graphs showing the results of cytotoxicity assays on two different human cell lines, JJN3 and U20S cells with various peptides, as described in Example 5.
  • (A) shows the growth of JJN3 cells in the presence of peptides alone, relative to no peptide;
  • (B) shows the growth of JJN3 cells in the presence of peptides and cisplatin, relative to cisplatin alone;
  • (C) shows the growth of U20S cells in the presence of peptides alone, relative to no peptide;
  • (D) shows the growth of U20S cells in the presence of peptides and cisplatin, relative to cisplatin alone.
  • ATX is SEQ ID NO: 918;
  • LVP is SEQ ID NO: 894; CO is no peptide added; and
  • Cis is cisplatin with no peptide added.
  • the numbers relate to the concentration of the peptide/cisplatin added, in ⁇ , i.e. "1 Cis+4ATX" means 1 ⁇ cisplatin + 4 ⁇ of ATX (SEQ ID NO: 918).
  • Figure 4 shows a graph showing the growth of E.coli BL21 in which the overexpression of a peptide motif of the invention (SEQ ID NO: 2) or an APIM peptide (RWLVK, SEQ ID NO: 914) is induced or not induced and demonstrates that the induction of these peptides inhibits bacterial growth.
  • SEQ ID NO: 2 a peptide motif of the invention
  • RWLVK APIM peptide
  • Figure 5 shows a graph showing the growth of E.coli BL21 1 , 3 and 5 hours after the addition of a peptide containing the motif of the invention (SEQ ID NO: 894) or a peptide containing an APIM sequence (SEQ ID NO:918) and
  • Figure 6 shows a graph depicting the mutation frequency for E.coli BL21 and E.coli BL21 with overexpression of a peptide motif of the invention (SEQ ID NO: 2) or an APIM peptide (RWLVK, SEQ ID NO:914). Data are shown for parallel (P) 1 to 7 and presented as means +/- SEM, and 2 hours after induction of UV.
  • SEQ ID NO: 2 a peptide motif of the invention
  • RWLVK APIM peptide
  • Figure 7 shows the mutation spectra of rpoB (1525-1722 bp, SEQ ID NOs: 921 (1525-1596bp) and 922 (1689-1722bp)) from rifampicin resistant colonies (A) pET28 empty vector not induced, (B) overexpression of an APIM-peptide (SEQ ID NO: 914) and (C) overexpression of the peptide motif of the invention (SEQ ID NO: 2). Data represent mutant colonies from different parallels. Spontaneous mutations are shown above sequence line and mutations found after UV exposure below line.
  • an oligopeptidic compound comprising a derivative of an APIM motif (that does not interact substantially with PCNA) and a cell-penetrating peptide is imported into bacterial cells and is capable of inhibiting the growth of said cells. Furthermore, said oligopeptidic compound is not cytotoxic to human cells. It is thought that oligopeptidic compounds of the invention may compete with the sliding clamp (e.g. ⁇ -clamp) protein in bacteria for proteins that interact with said sliding clamp protein, thereby inhibiting various cellular processes, e.g. DNA synthesis, signal transduction etc.
  • sliding clamp e.g. ⁇ -clamp
  • oligopeptidic compounds of the invention have been established in both gram positive and gram negative bacteria using an exemplary cell- penetrating peptide ATX-LVP (SEQ ID NO:894, which contains the motif, RLVPK (SEQ ID NO: 2)).
  • oligopeptidic compounds comprising SEQ ID NO: 2 are useful as anti-bacterial agents, e.g. antibiotics, and may be used either alone or in combination with other anti-bacterial agents. Accordingly, the data supports the use of oligopeptidic compounds comprising SEQ ID NO: 2 in the treatment or prevention of bacterial infections or bacterial infectious diseases.
  • Example 1 Determining the effect of peptides containing SEQ ID NO: 2 on bacteria
  • the anti-bacterial effect of the peptide motif of the invention was determined by overexpression of a peptide containing the motif in E.coli.
  • the activity of the peptide of the invention was compared to an APIM peptide, RWLVK (SEQ ID NO: 914).
  • a modified APIM peptide, RWLK (SEQ ID NO: 920) that does not interact substantially with PCNA was used as a negative control.
  • the peptides contain only the motif sequence, i.e. SEQ ID NO: 2 or the APIM sequence (i.e. without a cell-penetrating peptide) and were over-expressed in E.coli using the expression vector pET28.
  • the expression vectors containing the respective peptides were transfected into the bacterial strain E.coli BL21 (ripl). Single colonies, 4-6 of each strain, were inoculated in 150 ml LB media (+Km/Clm) in 96 wells plates, and incubated at 37°C. Overnight cultures were diluted 1 :100 and grown for 1 h before induction with 1 mM IPTG (initiating peptide expression). OD was measured every hour. Alternatively, growth was measured by counting colony forming units (CFUs) wherein dilutions for CFU were plated on LB-agar plates 1 , 3 and 5 hours after induction.
  • CFUs colony forming units
  • Figure 1 A shows that expression of an APIM peptide inhibits bacterial growth.
  • Figure 1 B shows that expression of a peptide comprising the motif of the invention (SEQ ID NO: 2) inhibits bacterial growth with a similar efficacy to the APIM peptide.
  • Figure 1 C shows that expression of a modified APIM peptide that does not interact substantially with PCNA does not inhibit bacterial growth.
  • Figure 4 shows bacterial growth of strains expressing the APIM motif (SEQ ID NO: 914) and the motif of the invention (SEQ ID NO: 2) as measured by CFU.
  • the Figure shows that expression of a peptide comprising the motif of the invention inhibits bacterial growth with a similar efficacy to the APIM peptide.
  • Example 2 Determination of the effect of UV radiation on the anti-bacterial properties of peptides containing SEQ ID NO: 2
  • Pre-cultures of E.coli BL21 were grown over-night in LB at 37°C. The cultures were then diluted 1 :100 and 150 ml/well was added/well in 96 wells plates. The cultures were further incubated for 1 h and each plate was exposed to UVC, 2 J/cm 2 , with a Stratalinker. The plates were incubated for 30 minutes following UV treatment and 15 ⁇ of various peptides were added to 6 parallel wells. OD 6 6o was measured every hour. Values were normalized and average was plotted.
  • Figure 2A shows the effect of APIM peptides (15 ⁇ ) on bacteria that have not been exposed to UV radiation.
  • the graph shows that a peptide containing the motif of the invention (SEQ ID NO: 2) has a significant inhibitory effect on bacterial growth, which is similar to the effect of an APIM containing peptide.
  • the R1 1 peptide (SEQ ID NO: 38), the cell-penetrating peptide (uptake peptide) that forms part of the tested peptides was used as a control.
  • the data shows that this peptide does not inhibit bacterial growth and further verifies that the motif of the invention is responsible for the anti-bacterial effects of the peptides of the invention.
  • Figure 2B is equivalent to Figure 2A when the bacteria have been exposed to UV radiation.
  • This Figure demonstrates that there is an additive effect when the the peptides of the invention are combined with UV radiation. This suggests that UV radiation sensitizes the cells to the peptides of the invention or vice versa.
  • UV radiation sensitizes the cells to the peptides of the invention or vice versa.
  • UVC radiation particularly UVC radiation
  • Microscale thermophoresis was used to determine the dissociation constant for various peptides.
  • the ⁇ -clamp protein from E.coli was labeled with a fluorescent molecule.
  • Table 3 shows that a peptide containing the motif of the invention has a specific interaction with the ⁇ -clamp protein (a low Kd value indicates a strong interaction, whereas a high Kd value indicates a weak interaction).
  • the interaction of the peptide of the invention is approximately 8 times stronger than the test APIM peptide (SEQ ID NO: 918).
  • a peptide containing a modified APIM sequence that does not interact substantially with PCNA also shows low affinity to the ⁇ -clamp protein.
  • the R1 1 peptide (SEQ ID NO: 38) was used as a control and no data could be obtained by MST for this peptide, indicating that this peptide does not interact with the ⁇ -clamp protein.
  • This data further verifies that the peptide motif of the invention (SEQ ID NO: 2) contributes to the anti-bacterial effects of the peptides of the invention.
  • the minimum inhibitory concentration (MIC) of peptides containing SEQ ID NO: 2 was determined for various gram negative and gram positive bacteria and compared to the MIC for a typical APIM containing peptide.
  • the bacteria
  • Pseudomonas aeruginosa ATCC 15692, Escherichia coli, Enterococcus faecium TO-3, Enterococcus faecium TO-12, Staphylococcus aureus MRSA 1040 and Staphylococcus aureus NCTC 6571 were grown in the presence of various concentrations of peptide, either ATX-LVP (SEQ ID NO:894) which contains the motif of the invention (SEQ ID NO: 2) or ATX-101 (SEQ ID NO: 918), which contains an APIM motif.
  • Robotic MIC assay
  • Each peptide was dissolved in Mueller-Hinton broth to 1 .25 times of the desired assay concentration.
  • TSB cultures inoculated from freeze stocks (6 ml in 50 ml tube tilted to 45-degrees angle, 200 rpm, 2.5 cm amplitude, 37 °C) were diluted in TSB until the OD600 was 0.10, and further diluted 1 :40 in Mueller- Hinton broth.
  • Each well in the 384-well assay plates was inoculated with 7.5 ⁇ of the diluted culture, giving the same dilution of the culture in the assay cultures.
  • the microplates were placed in plastic bags and incubated without shaking at 37 °C.
  • the optical density at 600 nm in the microwells was measured after approximately 19 hours of incubation, and the relative growth yield in each well was calculated based on the growth in the reference groups.
  • the MIC value was set to the highest concentration giving less than 30 % growth in all 4 parallel wells within the sample groups.
  • the microplates were further incubated for 6 hours, and optical density in the cultures was measured once more for confirmation of the estimated MIC- values.
  • the MICs for each peptide was determined for various bacteria and the results are shown in Table 4.
  • the results show that peptides containing the motif of the invention (SEQ ID NO: 2) have anti-bacterial properties, when used alone, across a variety of bacteria, including both gram negative bacteria (E.coli) and gram positive bacteria (S. aureus, E. faecium).
  • the peptide of the invention shows similar efficacy to the APIM containing peptide tested.
  • the results also demonstrate that peptides containing the motif of the invention are particularly effective against MDR bacteria, e.g. E.faecium TO-3 and MRSA 1040.
  • Example 5 Peptides containing SEQ ID NO: 2 are not cytotoxic to animal cells
  • the ATX-101 peptide (SEQ ID NO: 918), which contains an APIM sequence was used as a control.
  • JJN3 cells and U20S cells were seeded into 96 well plates (6000 cells/well) and incubated for 3 hours. After 24 hours peptides (4-1 ⁇ ) or peptides (4-1 ⁇ ) and cisplatin (1 -2 ⁇ ) were added to the cells in serum free media and incubated for 1 h. Fresh media was added and the cells were harvested after additional 24, 72 and 96 hours. MTT was added to the cells (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide) and OD was measured at 565 nm, and the average from at least 6 wells was used to calculate cell survival. Data is presented in Figure 3 as growth from one representative experiment and has been reproduced at least 2 times.
  • the results show that the peptide containing the motif of the invention, ATX- LVP (SEQ ID NO: 894), does not affect the growth of animal cells, i.e. the peptide is not cytotoxic to animal cells.
  • the APIM containing peptide, ATX-101 (SEQ ID NO: 918) inhibits the growth of animal cells and this effect is enhanced when combined with a cytotoxic agent, such as cisplatin.
  • the peptide of the invention does not show cytotoxicity in the assays even though it is used at higher concentrations than the APIM peptide, i.e. almost twice the concentration in the JJN3 assay.
  • cytotoxic activity of peptides comprising SEQ ID NO: 2 in animal cells demonstrates that peptides containing the motif on the invention would be particularly useful in the methods and uses defined herein as the peptides have similar anti-bacterial activity to peptides containing an APIM motif, but are not toxic to animal cells.
  • Example 6 Anti-bacterial activity of peptides containing SEQ ID NO: 2 by addition to E.coli BL21
  • peptides containing the motif of the invention (SEQ ID NO: 2) are capable of inhibiting bacterial growth
  • a peptide containing the motif coupled to a cell penetrating peptide (SEQ ID NO: 894) was added to a culture of E.coli BL21 at a concentration of 7 ⁇ . The growth of the bacteria was assessed by counting the number of CFUs.
  • a peptide containing an APIM sequence and the same cell penetrating peptide (SEQ ID NO: 918) was used as a control - this peptide has antibacterial activity.
  • Figure 5 shows that the peptide containing the motif of the invention was effective at reducing bacterial growth, having similar efficacy to the APIM peptide.
  • Example 7 Effect of peptide containing SEQ ID NO: 2 on mutation frequency in E.coli BL21
  • the frequency of rifR (mutations in the rpoB gene) was determined by calculating number of rifR per CFU.
  • OD 6 oo 0.3-0.4 inducing protein expression.
  • Diluted aliquots from the culture were mixed with 3 ml soft agar (LB agar plates with 0.5 % agar) and plated on LB agar plates (37°C, 16h) and LB agar plates with rifampicin (100 Mg/ml) (37°C, 48h). Some cultures were treated with UV (1.5 J/cm 3 ). Controls included uninduced and induced E.coli BL21 cells transfected with an empty pET28 vector.
  • Figure 6 shows the mutation frequency and demonstrates that expression of the peptide motif of the invention significantly reduces mutation frequency and has similar efficacy to the APIM sequence.
  • the peptide motif of the invention may impair the interaction between the ⁇ -clamp and translesion (TLS) polymerases, thereby inhibiting the activity of the TLS polymerases and their effects on mutation frequency.
  • TLS ⁇ -clamp and translesion
  • Figure 7 shows the mutation spectra of rpoB (1525-1722bp) from rifampicin resistant colonies in various E.coli cultures.
  • the figure demonstrates that the expression of the motif of the invention results in a change in mutation hotspots akin to an APIM peptide, which further supports the hypothesis that the peptide motif of the invention may impair the interaction between the ⁇ -clamp and translesion (TLS) polymerases.
  • TLS translesion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent ou une composition contenant un agent, destinés à être utilisés pour traiter ou prévenir une infection bactérienne chez un sujet, ledit agent comprenant : (i) un composé oligopeptidique comprenant la séquence d'acides aminés représentée dans SEQ ID NO : 2 et un domaine qui facilite l'absorption cellulaire dudit composé ; ou (ii) une molécule d'acide nucléique comprenant une séquence codant pour le composé oligopeptidique de (i). Selon certains aspects, l'agent et la composition selon l'invention peuvent être utilisés en tant qu'agents uniques. Dans d'autres aspects de l'invention, les agents et la composition peuvent être utilisés conjointement avec un ou plusieurs agents actifs supplémentaire(s), tels que des antibiotiques, ou en combinaison avec un rayonnement UV.
PCT/EP2016/060233 2015-05-06 2016-05-06 Agents antibactériens et utilisation thérapeutique de ceux-ci Ceased WO2016177900A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507723.3A GB201507723D0 (en) 2015-05-06 2015-05-06 Anti-bacterial agents and their use in therapy
GB1507723.3 2015-05-06

Publications (1)

Publication Number Publication Date
WO2016177900A1 true WO2016177900A1 (fr) 2016-11-10

Family

ID=53489190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/060233 Ceased WO2016177900A1 (fr) 2015-05-06 2016-05-06 Agents antibactériens et utilisation thérapeutique de ceux-ci

Country Status (2)

Country Link
GB (1) GB201507723D0 (fr)
WO (1) WO2016177900A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018197926A1 (fr) * 2017-04-26 2018-11-01 Robert Penchovsky Procédés de création de nouveaux agents antibactériens à l'aide d'oligonucléotides antisens chimériques
RU2688231C1 (ru) * 2019-02-19 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ лечения лептотрихоза ротовой полости
JP2020526574A (ja) * 2017-06-05 2020-08-31 ▲復▼旦大学Ｆｕｄａｎ Ｕｎｉｖｅｒｓｉｔｙ ポリペプチド類眼部吸収促進剤およびその応用
EP3801029A4 (fr) * 2018-05-30 2022-03-09 Morehouse School of Medicine Compositions antibactériennes, leurs procédés de fabrication et d'utilisation
WO2024011300A1 (fr) * 2022-07-13 2024-01-18 L'oreal Peptides modifiés, composition, procédé d'inhibition de la contraction de cellules musculaires, procédé d'amélioration de la peau et utilisation d'un peptide modifié
US12083159B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
WO2024222819A1 (fr) * 2023-04-26 2024-10-31 深圳信立泰药业股份有限公司 Inhibiteur de domaine psd-95, son procédé de préparation et son utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020532A1 (fr) * 1993-03-12 1994-09-15 Xoma Corporation Peptides biologiquement actifs issus de domaines fonctionnels de proteine bactericide/augmentant la permeabilite et utilisations de ladite proteine
WO2012054907A2 (fr) * 2010-10-22 2012-04-26 Boehringer Ingelheim Vetmedica S.A. De C.V. Nouvelles protéines d'hémagglutinine 5 (h5) pour le traitement et la prévention d'infections par la grippe
WO2015067713A1 (fr) * 2013-11-06 2015-05-14 Norwegian University Of Science And Technology (Ntnu) Agents antimicrobiens et leur utilisation en thérapie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020532A1 (fr) * 1993-03-12 1994-09-15 Xoma Corporation Peptides biologiquement actifs issus de domaines fonctionnels de proteine bactericide/augmentant la permeabilite et utilisations de ladite proteine
WO2012054907A2 (fr) * 2010-10-22 2012-04-26 Boehringer Ingelheim Vetmedica S.A. De C.V. Nouvelles protéines d'hémagglutinine 5 (h5) pour le traitement et la prévention d'infections par la grippe
WO2015067713A1 (fr) * 2013-11-06 2015-05-14 Norwegian University Of Science And Technology (Ntnu) Agents antimicrobiens et leur utilisation en thérapie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOMVANSHI P ET AL: "Prediction of Epitopes in Hemagglutinin and Neuraminidase Proteins of Influenza A Virus H5N1 Strain: A Clue for Diagnostic and Vaccine Development. OMICS", OMICS A JOURNAL OF INTEGRATIVE BIOLOGY, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 12, no. 1, 1 March 2008 (2008-03-01), pages 61 - 69, XP008140174, ISSN: 1536-2310, DOI: 10.1089/OMI.2007.0037 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083159B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
WO2018197926A1 (fr) * 2017-04-26 2018-11-01 Robert Penchovsky Procédés de création de nouveaux agents antibactériens à l'aide d'oligonucléotides antisens chimériques
JP2020526574A (ja) * 2017-06-05 2020-08-31 ▲復▼旦大学Ｆｕｄａｎ Ｕｎｉｖｅｒｓｉｔｙ ポリペプチド類眼部吸収促進剤およびその応用
EP3801029A4 (fr) * 2018-05-30 2022-03-09 Morehouse School of Medicine Compositions antibactériennes, leurs procédés de fabrication et d'utilisation
RU2688231C1 (ru) * 2019-02-19 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный медицинский университет имени академика Е.А. Вагнера" Министерства здравоохранения Российской Федерации Способ лечения лептотрихоза ротовой полости
WO2024011300A1 (fr) * 2022-07-13 2024-01-18 L'oreal Peptides modifiés, composition, procédé d'inhibition de la contraction de cellules musculaires, procédé d'amélioration de la peau et utilisation d'un peptide modifié
WO2024222819A1 (fr) * 2023-04-26 2024-10-31 深圳信立泰药业股份有限公司 Inhibiteur de domaine psd-95, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
GB201507723D0 (en) 2015-06-17

Similar Documents

Publication Publication Date Title
US11337427B2 (en) Antimicrobial agents and their use in therapy
US10570180B2 (en) Anti-bacterial agents and their use in therapy
WO2016177900A1 (fr) Agents antibactériens et utilisation thérapeutique de ceux-ci
US11246907B2 (en) Immunosuppressive agents and their use in therapy
WO2016177898A9 (fr) Agents immunosuppresseurs et leur utilisation en thérapie
JP5270150B2 (ja) 細菌感染の治療
EP3405222A2 (fr) Nouveaux polypeptides et leurs utilisations médicales
US20060121083A1 (en) Anti-microbial medical implants and uses thereof
Yoshida et al. Heparin–LL 37 complexes are less cytotoxic for human dental pulp cells and have undiminished antimicrobial and LPS‐neutralizing abilities
CN110582507A (zh) 工程化抗微生物两亲性肽及使用方法
US20100104607A1 (en) Anti-bacterial peptides and methods of treating diseases using same
KR20160140137A (ko) 결핵균 독소-항독소 체계를 표적으로 하는 항생 펩타이드 및 이의 용도
EP2349318A1 (fr) Synergie antibiotique
WO2018115877A2 (fr) Compositions et méthodes de traitement
CN103588861A (zh) 新德里金属β-内酰胺酶的抑制肽及其应用
EP1869185B1 (fr) Conjugué comprenant une protéine p21 dans le traitement du cancer
AU2019374135A1 (en) Inhibitors of Type 3 Secretion System and antibiotic therapy
WO2021078978A1 (fr) Ciment osseux antibactérien et ses utilisations
Zhou et al. Discovery and engineering of a novel peptide, Temporin-WY2, from frog skin secretion, with enhanced in vitro and in vivo antimicrobial efficacy against multi-drug resistant bacteria
WO2018104556A1 (fr) Peptides antimicrobiens
de Sousa Oliveira Exploring novel approaches to tackle Mycobacterium avium
JP5044765B2 (ja) 新規ペプチド、これを用いたエンドトキシン由来疾患治療剤およびこの治療剤の探索方法
WO2011115562A1 (fr) Composé antimicrobien
WO2005092365A2 (fr) Utilisation pharmaceutique des novispirines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16723973

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16723973

Country of ref document: EP

Kind code of ref document: A1